

2025 PDP BASIC Prior Authorization Criteria

# Actimmune

**Products Affected**

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# Adempas

---

**Products Affected**

- ADEMPAS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Pulmonary Arterial Hypertension, individual has a right heart catheterization showing all of the following: (a) Mean pulmonary artery pressure (mPAP) greater than or equal to 25 mm Hg at rest (b) Pulmonary capillary wedge pressure (PCWP), mean pulmonary artery wedge pressure (PAWP), left atrial pressure, or left ventricular end-diastolic pressure (LVEDP) less than or equal to 15 mm Hg (c) Pulmonary vascular resistance (PVR) greater than 3 Wood units. AND Individual has WHO functional class II- IV symptoms. For CTEPH a right-heart catheterization showing a mPAP greater than 25 mm Hg caused by thromboemboli in the pulmonary arterial system (ACCF/AHA 2009).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.

PA Criteria	Criteria Details
<b>Other Criteria</b>	For Initial use, for diagnosis of pulmonary arterial hypertension (PAH), WHO Group 1 AND has WHO functional class II-IV symptoms. For diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group 4 AND has WHO functional class II-IV symptoms AND using for one of the following: Persistent or recurrent pulmonary hypertension after at least 180 days following surgical treatment with pulmonary endarterectomy OR Inoperable (via pulmonary endarterectomy) CTEPH. For continued use, there is clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to improvement in walk distance, dyspnea and/or functional class).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AED Agents

## Products Affected

- DILANTIN ORAL CAPSULE 30 MG
- EPRONTIA
- FYCOMPA ORAL SUSPENSION
- FYCOMPA ORAL TABLET
- SPRITAM ORAL TABLET
- DISINTEGRATING SOLUBLE 1000 MG, 250 MG, 500 MG, 750 MG
- XCOPRI (250 MG DAILY DOSE) ORAL
- TABLET THERAPY PACK 100 & 150 MG
- XCOPRI (350 MG DAILY DOSE)
- XCOPRI ORAL TABLET 100 MG, 150 MG, 200 MG, 25 MG, 50 MG
- XCOPRI ORAL TABLET THERAPY PACK
- ZONISADE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has had a trial of and inadequate response or intolerance to ONE of the following preferred agents: Carbamazepine, Clonazepam/ODT, Clorazepate, Diazepam, Divalproex, Ethosuximide, Felbamate, Gabapentin, Lacosamide, Lamotrigine IR, Levetiracetam IR, Oxcarbazepine, Phenytoin, Primidone, Tiagabine, Topiramate IR, Valproate sodium, Valproic acid, Zonisamide OR the preferred agent is not FDA-approved for the prescribed indication.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# AFINITOR

---

## Products Affected

- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# Aimovig

---

## Products Affected

- AIMOVIG SUBCUTANEOUS  
SOLUTION AUTO-INJECTOR 140  
MG/ML, 70 MG/ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Episodic migraine defined as at least 4 and fewer than 15 migraine days per month and fewer than 15 headache days per month on average during the previous 3-month period. Chronic migraine defined as a headache occurring on 15 or more days per month for more than 3 months, which, on at least 8 days per month, has features of a migraine headache (ICHD-3 beta).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial: 3 months. Continuation: 1 year

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For initial requests: (I) Individual has a diagnosis of one of the following: (a) Episodic migraine OR (b) Chronic migraine AND (II) Individual is using for migraine prophylaxis. And (III) If individual is also currently using botulinum toxin for prophylaxis and is going to be using Aimovig and botulinum toxin together (i.e., not switching from one agent to another), the following will apply: (a) Individual has had a reduction in the overall number of migraine days or reduction in number of severe migraine days per month with the initial agent AND (b) Individual continues to experience a significant number of migraine headache days or severe migraine days per month requiring additional therapy for migraine prevention. For Renewal requests: (I) Individual has a reduction in the overall number of migraine days or reduction of severe migraine days per month AND (II) Individual has obtained clinical benefit deemed significant by individual or prescriber including any of the following (AHS 2019): (a) 50% reduction in frequency of days with headache or migraine OR (b) Significant decrease in attack duration OR (c) Significant decrease in attack severity OR (d) Improved response to acute treatment OR (e) Reduction in migraine-related disability and improvements in functioning in important areas of life OR (f) Improvements in health related quality of life and reduction in psychological stress due to migraine. AND If individual is using concurrently with botulinum toxin for migraine prophylaxis, the following will apply: Individual has had further reduction in the overall number of migraine days or reduction in number of severe migraine days per month compared to monotherapy with the initial agent (either botulinum toxin or CGRP).</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Akeega

---

**Products Affected**

- AKEEGA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For mCRPC, BRCA-mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual meets one of the following: (A) Individual is concomitantly receiving a gonadotropin-releasing hormone (GnRH) analog (e.g. Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix) OR (B) Has had a bilateral orchiectomy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Alecensa

---

## Products Affected

- ALECENSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Alpha1-Proteinase Inhibitor

## Products Affected

- PROLASTIN-C INTRAVENOUS SOLUTION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Initial use, verified alpha-1 antitrypsin level is less than or equal to 11micro-mol/L (approximately equivalent to 80mg/dL measured by radial immunodiffusion or 57 mg/dL measured by nephelometry) (ATS/ERS 2003, Stoller 2017). Individual has clinically evident emphysema (or chronic obstructive pulmonary disease [COPD]).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For Continued use, there is clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to decreased frequency of exacerbations, slowed rate of FEV1 decline, preservation of CT scan lung density or improvement in symptom burden).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Alunbrig

---

## Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For NSCLC, ALK mutation status.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# Amphetamine Salts

## Products Affected

- *amphetamine-dextroamphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	For dx ADHD, 3 years of age or older for immediate release. For Narcolepsy, 6 years of age or older for immediate release
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Ampyra

---

## Products Affected

- *dalfampridine er*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For renewal, individual achieved and sustained clinically significant improvement in ambulation related functional status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial approval 12 weeks, renewal 1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Arcalyst

## Products Affected

- ARCALYST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Written or verbal attestation is provided for confirmation of mutations where applicable based on use/diagnosis. For initial use, for DIRA, disease is in remission from previous anakinra treatment. For Recurrent Pericarditis (RP), individual is using for treatment of RP or reduction in risk of recurrence AND has a history of at least two pericarditis episodes (i.e. presents with at least the third episode) (Klein 2021).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For continued use, individual has been receiving and is maintained on a stable dose of Arcalyst AND mbr has clinically significant improvement or stabilization in clinical signs and symptoms of disease.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Augtyro

---

## Products Affected

- AUGTYRO ORAL CAPSULE 160 MG, 40 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For NSCLC, ROS1 mutation status. For solid tumor, NTRK gene fusion status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Auvelity

---

## Products Affected

- AUVELITY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For MDD.
<b>Age Restrictions</b>	Individual is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Ayvakit

---

## Products Affected

- AYVAKIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Advanced Systemic Mastocytosis (AdvSM) and Indolent Systemic Mastocytosis (ISM), individual has a platelet count of greater than or equal to 50 x 10 <sup>9</sup> /L. For GIST, PDGFRA exon 18 mutation status, including PDGFRA D842V mutation.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Balversa

---

## Products Affected

- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For mUC, written or verbal attestation is provided to confirm FGFR3 mutation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	Individual is using as a single agent.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# Banzel

## Products Affected

- *rufinamide oral suspension*
- *rufinamide oral tablet 200 mg, 400 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	Individual is 1 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has had a trial of and inadequate response or intolerance to ONE of the following preferred agents: Carbamazepine, Clonazepam/ODT, Clorazepate, Diazepam, Divalproex, Ethosuximide, Felbamate, Gabapentin, Lacosamide, Lamotrigine IR, Levetiracetam IR, Oxcarbazepine, Phenytoin, Primidone, Tiagabine, Topiramate IR, Valproate sodium, Valproic acid, Zonisamide OR the preferred agent is not FDA-approved for the prescribed indication.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Baraclude

## Products Affected

- BARACLUDGE ORAL SOLUTION
- *entecavir*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has a diagnosis of Chronic Hepatitis B virus (HBV) infection and has not been previously treated with lamivudine (AASLD 2016) OR is using as prophylaxis for hepatitis B reactivation in the setting of immune suppression (AGA 2015) or in combination with hepatitis C direct-acting antiviral therapy (AASLD 2017) OR Individual is a solid organ transplant recipient and using as prophylaxis for hepatitis B reactivation post (AASLD 2018).
<b>Age Restrictions</b>	2 years of age and older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Benlysta

---

## Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial: 6 months. Continuation: 1 Year.

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For initial tx (IV or Subcutaneous), individual has a diagnosis of SLE per the American College of Rheumatology [ACR] criteria AND has positive ANA titer greater than or equal to 1:80 or anti-dsDNA greater than or equal to 30 IU/mL AND disease is active as shown by a SELENA-SLEDAI score greater than or equal to 6 while on current treatment regimen AND SLE remains active while on corticosteroid, antimalarials, and/or immunosuppressants for at least the last 30 days AND is using in combination with standard therapy (for example, corticosteroids, antimalarials, and/or immunosuppressants [but not other biologics or IV cyclophosphamide]). For Initial tx (IV or Subcutaneous) of active lupus nephritis, individual has Class III, IV, or V lupus nephritis showing active or chronic lesions, and confirmed by renal biopsy AND has a urinary protein to creatinine ratio of greater than or equal to 1 AND did not have disease progression to lupus nephritis while on Benlysta therapy for SLE without LN AND disease remains active while on corticosteroids, antimalarials, or immunosuppressants (alone or as combination therapy) for at least the last 30 days AND is using in combination with standard therapy (for example, corticosteroids, antimalarials, and/or immunosuppressants [but not other biologics or IV cyclophosphamide]). For continuation of therapy (IV or Subcutaneous), verification of previous improvement in disease activity following treatment with belimumab indicating a therapeutic response including lack of disease progression to lupus nephritis while on Benlysta if initially only using for SLE without LN AND there is no evidence of active central nervous system lupus. AND individual is using in combination with standard therapy (for example, corticosteroids, antimalarials, and/or immunosuppressants [but not other biologics or IV cyclophosphamide]).</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Besremi

---

## Products Affected

- BESREMI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Bosulif

---

## Products Affected

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	The individual has one of the following mutations: T315I, V299L, G250E, or F317L.
<b>Required Medical Information</b>	For CML/ALL, Philadelphia Chromosome status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Braftovi

---

## Products Affected

- BRAFTOVI ORAL CAPSULE 75 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis, BRAF V600 status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Bronchitol

---

## Products Affected

- BRONCHITOL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has a prescription for a short-acting bronchodilator and will be administering prior to every dose of mannitol AND has had a trial and inadequate response or intolerance to inhaled hypertonic saline (Mogayzel 2013).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Brukinsa

---

## Products Affected

- BRUKINSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Individual has no prior BTK inhibitor usage.
Age Restrictions	Individual is 18 years of age or older.
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# Buphenyl

## Products Affected

- *sodium phenylbutyrate oral powder 3 gm/tsp*
- *sodium phenylbutyrate oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Using as adjunctive therapy for chronic management of hyperammonemia
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For continuation, there is clinically significant improvement or stabilization in plasma ammonia level.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Cabometyx

---

## Products Affected

- CABOMETYX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Calquence

---

## Products Affected

- CALQUENCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# Caprelsa

---

## Products Affected

- CAPRELSA ORAL TABLET 100 MG, 300 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No



# Carbaglu

## Products Affected

- *carglumic acid oral tablet soluble*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For initial use, (A) member has a diagnosis of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) AND Using as adjunctive therapy with other ammonia lowering therapies OR (B) has a diagnosis of chronic hyperammonemia due to the deficiency of the hepatic enzyme NAGS AND Using as maintenance therapy OR (C) Individual is using as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MA) and using as adjunctive therapy with other ammonia lowering therapies. For Continuation use, there is clinically significant improvement or stabilization in plasma ammonia level.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Cayston

---

## Products Affected

- CAYSTON

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	7 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Chantix

---

## Products Affected

- *varenicline tartrate (starter)*
- *varenicline tartrate oral tablet 0.5 mg, 1 mg, 1 mg (56 pack)*
- *varenicline tartrate(continue)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Cialis BPH

---

## Products Affected

- *tadalafil oral tablet 5 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has a diagnosis of benign prostatic hyperplasia (BPH) and is using to treat the signs and symptoms of BPH.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has had a trial and inadequate response or intolerance to TWO of the following agents: Alfuzosin, Doxazosin, Silodosin, Tamsulosin, or Terazosin.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Cometriq

## Products Affected

- COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Copiktra

---

## Products Affected

- COPIKTRA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For continuation, confirmation (verbal or written) of continuing clinical benefit (e.g., complete response, partial response or stable disease).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 YEAR.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Corlanor

## Products Affected

- *ivabradine hcl*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	For dx NYHA class II-IV (Adult) HF, individual is 18 years of age or older. For NYHA class II-IV (Pediatric) HF due to CM, individual is less than 18 years of age.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For INITIAL use: (A) For adult use, Individual is using for the treatment of New York Heart Association (NYHA) class II, III or IV heart failure symptoms AND has a left ventricular ejection fraction less than or equal to 35% AND will be utilizing in combination with a beta-blocker (bisoprolol, carvedilol, metoprolol succinate) OR has a contraindication or intolerance to beta-blocker therapy AND is in normal sinus rhythm AND individual has a resting heart rate greater than or equal to 70 beats per minute. OR (B) For pediatric use, Individual is using for the treatment of New York Heart Association (NYHA) class II, III, or IV heart failure symptoms due to dilated cardiomyopathy AND has a left ventricular ejection fraction less than or equal to 45% AND is in normal sinus rhythm AND individual has an elevated resting heart rate. For Continuation use there is clinically significant improvement or stabilization in clinical signs and symptoms of disease.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Cotellic

## Products Affected

- COTELLIC

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Melanoma, written or verbal attestation is provided to confirm BRAF V600 mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For unresectable or metastatic melanoma, Individual is using in combination with Zelboraf (vemurafenib) with or without Tecentriq (atezolizumab).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Cystagon

---

## Products Affected

- CYSTAGON

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# Daliresp

---

## Products Affected

- *roflumilast oral tablet 500 mcg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	Individual is using in combination with a long-acting bronchodilator.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Danziten

---

## Products Affected

- DANZITEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For CML, Ph status, T315I, Y253H, E255K/V, F359V/C/I or G250E status.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Daraprim

---

## Products Affected

- *pyrimethamine oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual is using in combination with leucovorin AND Individual is using to treat toxoplasmosis AND is using in combination with a sulfonamide unless CI or not tolerated.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Daurismo

---

## Products Affected

- DAURISMO ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individual is 75 years old or older OR has comorbidities that preclude use of intensive induction chemotherapy.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# DHE Nasal Agents

## Products Affected

- *dihydroergotamine mesylate nasal*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has had a trial of and inadequate response or intolerance to up to TWO of the following oral agents: Almotriptan, eletriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan OR If oral triptan agents are not acceptable due to concomitant clinical conditions, such as but not limited to the following: (A) Individual is unable to take oral medications due to one of the following: (1) Individual experiences nausea and vomiting due to migraines OR (2) requires a more rapid onset of action due to short aura time period OR (3) cannot swallow tablets and there are no preferred ODT (oral disintegrating tablet) formulations.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Diacomit

## Products Affected

- DIACOMIT ORAL CAPSULE 250 MG, 500 MG
- DIACOMIT ORAL PACKET 250 MG, 500 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For dx of seizures associated with Dravet Syndrome AND is taking in combination with clobazam AND has responded inadequately to TWO previous antiepileptic drugs (e.g. valproic acid, topiramate, clobazam) (Wirrell 2017, Ziobro 2018).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Dificid

---

## Products Affected

- DIFICID ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	30 Days
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Dimethyl Fumarate

---

## Products Affected

- *dimethyl fumarate oral capsule delayed release 120 mg, 240 mg*
- *dimethyl fumarate starter pack oral capsule delayed release therapy pack*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has a diagnosis of relapsing multiple sclerosis (RMS) (including clinically isolated syndrome, relapsing-remitting disease or active secondary progressive disease).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Dupixent

## Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/1.14ML, 300 MG/2ML SOLUTION PREFILLED SYRINGE 100 MG/0.67ML, 200 MG/1.14ML, 300 MG/2ML
- DUPIXENT SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>For initial dx of mod-severe asthma as demon by (NHLBI 2020): (a) FEV1 reversibility of at least 12% and 200ml after albuterol admin. For initial dx of CRSwNP, dx is demonstrated (demo) by (AAO-HNSF 2015): (a) Anterior rhinoscopy or (b) Nasal endoscopy or (c) CT scan. For initial use in atopic derm (AD), has tried ONE of the following and treatment failed to achieve and maintain remission of low or mild disease activity A) Topical calcineurin inhibitors (2 yrs of age or older) OR B) Phototherapy (UVB or PUVA) OR C) Non-corticosteroid systemic immunosuppressants (2 yrs of age or older) OR D) has CI to TCI AND Non-corticosteroid systemic immunosuppressants AND unable to use Phototherapy. For initial EoE, mbr has 15 or more intraepithelial eos/hpf (NCT03633617) AND has Symptoms of dysphagia (NCT03633617) AND tried a course of (PPIs) (Hirano,2020) AND tried a course of glucocorticoids (Hirano, 2020). For Initial COPD, mbr has a blood eos count of at least 300 per microliter (Bhatt 2023) AND dx is demo by post-bronchodilator (BD) FEV1/FVC less than 0.7 (Bhatt 2023, GOLD 2024) AND has mod to sev airflow obstruction demo by post-BD FEV1 30-70% predicted normal value (Bhatt 2023) AND meets one of the following (Bhatt 2023) (1 or 2): (1) At least one (1) hospitalization or more than 24 hours of medical observation related to COPD in the past twelve (12) months OR (2) In the past 12 months, at least two mod COPD exacerbations and req systemic steroids for at least one exacerbation AND meets one of the following (Bhatt 2023) (A or B): (A) is on a stable dose of LAMA-LABA therapy including inhaled glucocorticoid OR (B) mbr is unable to use an inhaled glucocorticoid due to a medical reason and is on a stable dose of LAMA-LABA therapy.</p>

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial: 6 months. Continuation: 1 Year.

PA Criteria	Criteria Details
<p><b>Other Criteria</b></p>	<p>For initial tx of Asthma, (A) indiv has one of the following: (i) has a blood eosinophil count (in the absence of other potential causes of eosinophilia, including HES, neoplastic dz, and known or suspected parasitic infection) gtr than or equal to 150 cells/microliter at initiation AND (ii) has had a 3 month trial and inadeq resp or intolerance to combo controller therapy (med-to-high dose inhaled steroids plus long acting beta2 -agonists, leukotriene modifiers, theophylline or oral steroids) (ERS/ATS 2013). OR (iii) has oral steroid dependent asthma AND (iv) has had a 3 month trial and inadequate resp or intol to high dose inhaled steroid with daily oral glucocorticoids given in combo with a controller medication (either a long-acting beta2-agonist, or leukotriene receptor antagonist, or theophylline) (ERS/ATS 2013) AND (B) indiv has exp two or more asthma exacerbations in the prior 12 months req use of a systemic steroid or temp inc in the mbrs usual maint dosage of oral steroids. For cont tx of asthma: (a) mbr has exp one or more of the following: (i) Dec utilization of reliever meds OR (ii) Dec freq of exacerbations (defined as worsening of asthma that req an incr in inhaled steroid dose or tx with systemic steroids) OR (iii) Inc in predicted FEV1 from pretx baseline OR (iv) Red in reported asthma-related symptoms, such as, asthmatic symptoms upon awakening, coughing, fatigue, shortness of breath, sleep disturbance, or wheezing AND continues to use in combination with inhaled corticosteroid-based controller therapy. For initial dx CRSwNP, mbr has had a recent trial and inadequate resp to maint intranasal steroid (AAO-HNSF 2015) AND had trial, inadequate resp or intolerance to or has CI to the following: (a) Systemic steroids or (b) Sino-nasal surgery AND is using dupilumab as add on therapy to maint intranasal steroid. For initial PN mbr has tried one of the following and treatment failed to achieve and maintain remission of low or mild disease activity: med to super potent topical corticosteroids OR TCI. For cont use COPD, using in combo with LAMA/LABA therapy OR ICS/LAMA/LABA therapy unless not tolerated AND resulted in clinical improvement in one or more of</p>
	<p>the following: Dec utilization of reliever medication OR Dec freq or severity of exacerbations OR Reduction in reported COPD-related symptoms, including SOB, cough, fatigue or sleep disturbance. For cont use for CRSwNP/EoE/PN/AD, clinically significant imp or stabilization in clinical signs and symptoms of dz.</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Duragesic Patch

---

## Products Affected

- *fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individual is 2 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial 3 months. Maintenance 6 months. Cancer Pain/Terminal Dx or Palliative Care 1 Year.



PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For initial use, Individual has one of the following: (a) Diagnosis of cancer related pain and/or is actively undergoing cancer therapy (provide cancer diagnosis) OR (b) Diagnosis of terminal illness and is receiving palliative/end-of-life care (provide terminal diagnosis) OR Individual has pain severe enough to require daily, around-the-clock, long term opioid treatment (provide diagnosis) AND Individual has one of the following: (a) An inadequate response to ONE alternative treatment options, such as but not limited to non-opioid analgesics and immediate-release opioids OR (b) Alternative treatment options would otherwise be inadequate to provide sufficient management of pain OR (c) Individual has contraindications to non-opioid analgesics (such as NSAID use in individuals with active ulcer condition/gastrointestinal bleeding, renal failure) AND Individual is not opioid naive as noted by the following: (a) Individual is currently using a short-acting opioid analgesic, including use of opioid analgesia as an inpatient for post-surgical pain OR (b) Individual is transitioning from one long-acting opioid analgesic to another long-acting opioid analgesic OR (c) already receiving at least 60 mg/day of oral morphine, 30 mg/day of oral oxycodone, 8 mg/day of oral hydromorphone, 60 mg/day of oral hydrocodone or an equianalgesic dose of another opioid. For continued use, (I) individual has a diagnosis of cancer related pain and/or is actively undergoing cancer therapy (provide cancer diagnosis) OR (II) diagnosis of terminal illness and is receiving palliative/end-of-life care (provide terminal diagnosis) OR (III) Individual has pain severe enough to require daily, around-the-clock, long term opioid treatment (provide diagnosis) AND Attestation (verbal or written) that long-acting opioid therapy has provided meaningful improvement in pain and/or function compared to baseline AND prescriber has consulted with individual regarding risks of opioid therapy AND clear treatment goals have been defined and outlined as part of overall pain.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Elidel

## Products Affected

- *pimecrolimus*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individual is 2 years of age and older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Individual is using as second-line therapy for mild to moderate atopic dermatitis AND has had a trial of and inadequate response or intolerance to one topical prescription strength corticosteroid.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Emsam

---

## Products Affected

- EMSAM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has no known contraindications to the use of a monoamine oxidase inhibitor (MAOI).
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Enbrel

## Products Affected

- ENBREL MINI MG/ML
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML • ENBREL SURECLICK
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25 MG/0.5ML, 50 SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For chronic moderate to severe plaque psoriasis with either of the following: Individual has greater than 3% of body surface area with plaque psoriasis OR less than or equal to 3% of body surface area with plaque psoriasis involving sensitive areas or areas that would significantly impact daily function (such as palms, soles of feet, head/neck, or genitalia).
<b>Age Restrictions</b>	Individual is 18 years of age or older, except for the diagnosis of JIA and plaque psoriasis. For PsA and JIA, individual is 2 years of age or older. For plaque psoriasis, 4 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For Initial use: moderate to severe Ankylosing Spondylitis, individual has had an inadequate response to, or is intolerant of, ONE conventional therapies: [such as NSAIDs or nonbiologic DMARDs (such as sulfasalazine)] (ACR 2019) OR has a contraindication to NSAIDs or sulfasalazine. For Moderate to severe Chronic Plaque Psoriasis, individual has had inadequate response to, or is intolerant of, phototherapy OR ONE other systemic therapies (such as, methotrexate, acitretin, or cyclosporine) has a contraindication to phototherapy, acitretin, cyclosporine, and methotrexate. For moderate to severe Rheumatoid Arthritis, individual has had an inadequate response to, methotrexate titrated to maximally tolerated dose (ACR 2021) OR If methotrexate is not tolerated, individual has had an inadequate response to, or is intolerant of, ONE other conventional therapy (sulfasalazine, leflunomide, or hydroxychloroquine) OR has a contraindication to methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine. For moderate to severe Polyarticular JIA, individual has had an inadequate response to, or is intolerant of, ONE conventional therapy [nonbiologic DMARDs such as methotrexate] (ACR 2019) OR has a contraindication to methotrexate. For moderate to severe Psoriatic Arthritis, individual has had an inadequate response to, or is intolerant of, ONE conventional therapy [nonbiologic DMARDs (such as methotrexate, sulfasalazine or leflunomide)] (AAD 2019) OR has a contraindication to methotrexate, sulfasalazine, cyclosporine, and leflunomide. For Continuation use: there is clinically significant improvement or stabilization in clinical signs and symptoms of the disease AND has been receiving and is maintained on a stable dose of etanercept.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Endari

---

## Products Affected

- *L-glutamine oral packet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For initial, individual has a diagnosis of sickle cell anemia with following: (A) Diagnosis of HbSS or HbS/beta0- thalassemia AND (B) At least two episodes of sickle cell crises (SCC) in the last 12 months.
<b>Age Restrictions</b>	Individual is 5 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For continuation, individual experienced a reduction in acute complications of sickle cell disease (e.g. reduction in the number of vaso-occlusive episodes, acute chest syndrome episodes) since initiating Endari (L-glutamine).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Epclusa

## Products Affected

- EPCLUSA ORAL PACKET 150-37.5 MG, 200-50 MG
- EPCLUSA ORAL TABLET 200-50 MG, 400-100 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation is provided for a diagnosis of chronic hepatitis C (CHC) infection, which includes genotype and positive HCV RNA result (AASLD/IDSA 2017, CDC 2013) AND Individual has received baseline evaluation for liver fibrosis to guide appropriate therapy AND Individual does not have a short life expectancy (less than 12 months owing to non-liver related comorbid conditions) that cannot be remediated by treating HCV, by transplantation or other directed therapy (AASLD/IDSA 2016).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.
<b>Other Criteria</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Epidiolex

## Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For tx of seizures associated with Lennox-Gastaut syndrome or Dravet Syndrome, Individual has responded inadequately to two previous antiepileptic drugs (e.g., valproic acid, topiramate, clobazam) (Hancock 2013. Wirrell 2017. Ziobro 2018). Individual is using for tuberous sclerosis complex.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Epogen and Procrit

---

## Products Affected

- PROCRIT

PA Criteria	Criteria Details
Exclusion Criteria	

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p>For initial use of EPO: Baseline Hemoglobin (Hgb) levels are less than 10 g/dL AND baseline evaluation of the individual iron status is adequate as defined by one of the following: transferrin saturation 20% or greater OR ferritin 80 ng/mL or greater OR bone marrow demonstrates adequate iron stores. And individual is using for one of the following: For MDS, endogenous EPO level is less than or equal to 500 mU/ml. For anemia related to zidovudine (ZDV) in HIV-infected mbr when the dose of ZDV is less than or equal to 4200 mg per week, endogenous EPO level is less than or equal 500 mU/ml. For tx of anemia due to myelosuppressive chemotherapy known to produce anemia when the following are met: chemo is planned for a minimum of 2 months and the dx is non-myeloid cancer and the anticipated outcome is not cure. For anemia associated with CKD ON dialysis use is to achieve and maintain hgb levels within the range of 10 to 11 g/dL. For anemia associated with CKD NOT ON dialysis, use is to achieve and maintain hgb levels of 10 g/dL. For continued use, mbr demonstrates continued need for ESA tx and has confirmation of response to tx as evidenced by an inc in HGB levels from baseline AND is using the lowest ESA dose necessary to avoid transfusions AND meets one of the following criteria: (a) HGB level is not greater than 11 g/dL for CKD individuals on dialysis, or greater than 10 g/dL for CKD non-dialysis, unless otherwise specified (for example, pediatric individuals with CKD where target Hgb levels is within the range of 10 to 12 g/dL) OR (b) HGB is not greater than 11 g/dL for indiv using for myelosuppressive chemotherapy related anemia or myelodysplastic syndrome (NCCN) OR HGB level is not greater than 12 g/dL for ZDV-related anemia in patients with HIV AND if using for myelosuppressive chemotherapy-related anemia, individual is not using beyond 6 weeks after chemotherapy has completed.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Dialysis Dependent use: 1 year. All other use: 6 months.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	For ESA use for elective, non-cardiac, non-vascular surgery to reduce the need for allogenic blood transfusions AND Baseline Hgb level is greater than 10 g/dL and less than or equal to 13 g/dL AND is at high risk for perioperative transfusions with significant, anticipated blood loss AND Baseline iron status is adequate as defined by one of the following: (i) Transferrin saturation 20% or greater OR (ii) Ferritin 80 ng/mL or greater OR (iii) Bone marrow demonstrates adequate iron stores.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Erivedge

---

## Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For continuation, individual does not show evidence of progressive disease while on vismodegib therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Erleada

## Products Affected

- ERLEADA ORAL TABLET 240 MG, 60 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual is concomitantly receiving a gonadotropin-releasing hormone (GnRH) analog [e.g. Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix)] OR Has had a bilateral orchiectomy. For non-metastatic castration-resistant prostate cancer (nmCRPC), Individual has a PSA doubling time (PSADT) less than or equal to 10 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Erwinase

---

## Products Affected

- RYLAZE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has developed a confirmed (written or verbal) systemic allergic reaction or anaphylaxis to prior treatment with E. Coli-derived asparaginase.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Esbriet

## Products Affected

- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Initial use for Diagnosis of idiopathic pulmonary fibrosis (IPF) demonstrated by: Exclusion of other known causes of interstitial lung disease (ILD) such as domestic and occupational environmental exposures, connective tissue disease, and drug toxicity AND High resolution computed tomography (HRCT) with or without lung tissue sampling. Individual has pulmonary function tests within prior 60 days demonstrating a Forced Vital Capacity (% FVC) greater than or equal to 50%.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For continued use, there is clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to decreased frequency of exacerbations, slowed rate of FVC decline or improvement in respiratory symptom burden).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Exjade

---

## Products Affected

- *deferasirox oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Individual is 2 years of age or older
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No



# Exkivity

---

## Products Affected

- EXKIVITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Written or verbal attestation is provided for confirmation of mutations where applicable based on use/diagnosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has not progressed on prior therapy with Exkivity (mobocertinib) AND is using as monotherapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Faslodex

---

## Products Affected

- *fulvestrant intramuscular solution  
prefilled syringe*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Fetzima

---

## Products Affected

- FETZIMA
- FETZIMA TITRATION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For MDD, individual has had a trial of TWO of the following: Desvenlafaxine, fluoxetine, fluvoxamine, escitalopram, citalopram, paroxetine, sertraline, mirtazapine, venlafaxine, or bupropion.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Fintepla

---

## Products Affected

- FINTEPLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Individual is using for weight loss/reduction.
<b>Required Medical Information</b>	Diagnosis: Lennox-Gastaut syndrome (LGS), Dravet Syndrome (DS).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has a diagnosis of seizures associated with Lennox-Gastaut syndrome or Dravet Syndrome AND has responded inadequately to two previous antiepileptic drugs (Lagae 2019, Wirrell 2017, Ziobro 2018).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Firazyr

## Products Affected

- *icatibant acetate subcutaneous solution prefilled syringe*
- SAJAZIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Prophylaxis for HAE attacks.
<b>Required Medical Information</b>	Dx of HAE to be verified by a C4 level below the lower limit of normal (as defined by laboratory testing) and either a C1 inhibitor antigenic level below the lower limit of normal (as defined by lab testing) or a C1 inhibitor functional level below the lower limit of normal (as defined by the lab testing).
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has a history of moderate or severe attacks such as airway swelling, severe abdominal pain, facial swelling, nausea and vomiting, or painful facial distortion and using Icatibant for acute HAE attacks.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Firmagon

## Products Affected

- FIRMAGON (240 MG DOSE)
- FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Prostate cancer: Clinically localized disease with intermediate (T2b to T2c cancer, Gleason score of 7/Gleason grade group 2-3, or prostate specific antigen (PSA) value of 10-20 ng/mL) OR higher risk of recurrence as neoadjuvant therapy with radiation therapy or cryosurgery OR Used for progressive castration-na?ve disease or for castration-recurrent disease OR Other advanced, recurrent, or metastatic disease.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Forteo

## Products Affected

- *teriparatide subcutaneous solution pen-injector 620 mcg/2.48ml*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Osteoporosis is defined as a BMD T-Score in the spine, femoral neck, total hip or distal 1/3 of the radius of less than or equal to -2.5 as compared to young adult reference population OR a Clinical diagnosis based on a history of a low trauma fracture (fragility fracture) at high risk for fracture OR associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5mg or greater of prednisone for at least 3 months) at high risk for fracture.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For initial use, Individual meets one of the following: (A) Individual has been refractory to a trial of a oral bisphosphonate therapy OR (B) Intolerance or contraindications to oral bisphosphonate as defined by having at least one of the following: 1. Hypersensitivity to TWO oral bisphosphonates (one of which must be alendronate) 2. Inability to sit or stand upright for at least 30 minutes, 3. Pre-existing gastrointestinal disorders (Barrett's esophagus, hypersecretory disorders, delayed esophageal emptying, etc.). 4. Uncorrected hypocalcemia. 5. Severe renal insufficiency as defined by creatinine clearance less than 35 mL/min for alendronate agents and zoledronic acid or creatinine clearance less than 30 mL/min for risedronate and ibandronate. OR (C) Individual is a postmenopausal female at very high risk for fracture as defined by one or more of the following (AACE/ACE 2020): Recent fracture (within the past 12 months), Fractures while on approved osteoporosis therapy, Multiple fractures, Fractures while on drugs causing skeletal harm (e.g. long-term glucocorticoids), Very low T-score (less than -3.0), High risk for falls or history of injurious falls, or Very high fracture probability by FRAX (fracture risk assessment tool) (e.g. major osteoporosis fracture greater than 30%, hip fracture greater than 4.5%) or other validated fracture risk algorithm. AND has ONE of the following dx: 1. mbr is a postmenopausal female with a diagnosis of osteoporosis at high for fracture OR 2. Mbr has osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture OR 3. male diagnosed with primary or hypogonadal osteoporosis at high risk for fracture using to inc bone mass. For continued use, there is clinically significant response to therapy (including but not limited to no new fractures reduction of fractures, or no worsening vertebral fractures, or no clinically significant adverse reaction) AND IF mbr has been on therapy less than or equal to 24 months of treatment, a repeat BMD demonstrates a stable or increase in BMD.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Fotivda

---

## Products Affected

- FOTIVDA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For RCC, individual has received at least two prior systemic therapies AND at least one prior systemic therapy included a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI), such as axitinib, cabozantinib, lenvatinib, sunitinib, or pazopanib (Rini 2020).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Fruzaqla

---

## Products Affected

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Individual is using as a single agent.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Gattex

## Products Affected

- GATTEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial: 7 months, Continuation: 1 Year.
<b>Other Criteria</b>	For initial use, in the diagnosis of Short Bowel Syndrome (SBS) individual is dependent on parenteral nutrition (PN) support, requires PN at least 3 times per week (O Keefe 2013). For continued use, individual has experienced improvement as compared to baseline.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Gavreto

## Products Affected

- GAVRETO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has written or verbal confirmation of RET fusion (or rearrangement) positive tumors. For NSCLC, individual has not received treatment with another RET rearrangement positive-targeted agent, such as cabozantinib, vandetanib, or selpercatinib (NCT03037385).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual is using as monotherapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Gilenya

## Products Affected

- *fingolimod hcl*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>I. Individual has had a trial and inadequate response (including but not limited to clinical relapse, new or enlarged lesions on MRI or disability progression) or intolerance to one of the following: Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Glatiramer Acetate/Glatopa, Dimethyl Fumarate, or Teriflunomide OR II. Individual has high disease activity despite treatment with a disease modifying drug (including Aubagio, Avonex, Bafiertam, Extavia, Kesimpta, Plegridy, Ponvory Rebif, Betaseron, Briumvi Lemtrada, Mavenclad, Mayzent, Ocrevus, Copaxone/Glatiramer/Glatopa, Tecfidera, Tysabri, Vumerity and Zeposia) defined as the following: At least 1 relapse in the previous year while on therapy AND At least 9 T2-hyperintense lesions in cranial MRI OR At least 1 Gadolinium-enhancing lesion. OR III. Individual is treatment naive (no previous history of use of disease modifying drugs such as Aubagio, Avonex, Bafiertam, Betaseron, Briumvi, Copaxone/Glatiramer/Glatopa, Extavia, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Plegridy, Ponvory Rebif, Tecfidera, Tysabri, Vumerity and Zeposia) AND IV. Individual has rapidly evolving severe relapsing multiple sclerosis defined as the following: Two or more disabling relapses in 1 year AND One or more Gadolinium-enhancing lesions on brain MRI. OR V. Individual is between 10-17 years of age and has a diagnosis relapsing MS (RMS).</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Gilotrif

---

## Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For NSCLC, EGFR mutation status.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# Glatiramer Agents

## Products Affected

- *glatiramer acetate subcutaneous solution*      MG/ML, 40 MG/ML  
*prefilled syringe 20 mg/ml, 40 mg/ml*
- GLATOPA SUBCUTANEOUS  
SOLUTION PREFILLED SYRINGE 20

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has relapsing multiple sclerosis (RMS) (including clinically isolated syndrome, relapsing-remitting disease or active secondary progressive disease)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Gleevec

## Products Affected

- *imatinib mesylate oral tablet 100 mg, 400 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For ASM written or verbal attestation is provided to confirm D816V c-Kit mutation status. For CML/ALL Philadelphia chromosome (Ph) status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Gleostine

---

**Products Affected**

- GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GLP 1

## Products Affected

- OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/1.5ML, 2 MG/3ML
- OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/1.5ML, 4 MG/3ML
- OZEMPIC (2 MG/DOSE)
- RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG
- TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Individual is using for weight loss.
<b>Required Medical Information</b>	Documentation (written) has been provided for diagnosis. Attestation has been provided that diagnosis has been verified by history of: (A) Hemoglobin A1c (A1C) greater than or equal to 6.5% OR (B) Fasting Plasma Glucose (FPG) greater than or equal to 126 mg/dl (after fasting for at least 8 hours) OR (C) 2 hour plasma glucose greater than or equal to 200mg/dl as part of an oral glucose tolerance test (75g oral glucose after fasting for at least 8 hours) OR (D) Symptoms of hyperglycemia (including polyuria, polydipsia, polyphagia) or hyperglycemic crisis and a random plasma glucose greater than or equal to 200 mg/dl.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For Type 2 Diabetes.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Haegarda

---

## Products Affected

- HAEGARDA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individual is 6 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial: 6 months. Continuation: 1 Year.
<b>Other Criteria</b>	Individual has a history of moderate or severe attacks and is using as prophylaxis against acute attacks of hereditary angioedema for short-term use prior to surgery, dental procedures, or intubation OR for long-term prophylaxis to minimize the frequency and/or severity of recurrent attacks.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Harvoni

## Products Affected

- HARVONI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation is provided for a diagnosis of chronic Hepatitis C virus (CHC) infection, which includes Genotype and a positive HCV RNA result (AASLD/IDSA 2017, CDC 2013) AND Individual has received baseline evaluation for liver fibrosis to guide appropriate therapy AND Individual does not have a short life expectancy (less than 12 months owing to non-liver related comorbid conditions) that cannot be remediated by treating HCV, by transplantation or other directed therapy (AASLD/IDSA 2016).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.
<b>Other Criteria</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Hepsera

## Products Affected

- *adefovir dipivoxil*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	12 years of age and older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Individual has had a previous trial and inadequate response or intolerance to or has a contraindication to an alternative antiviral agent with a higher genetic barrier to resistance for Hepatitis B [such as entecavir or tenofovir] (AASLD 2016).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Hetlioz

## Products Affected

- *tasimelteon*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Initial use, individual has a dx of non-24-hour sleep-wake disorder OR has Smith-Magenis Syndrome (SMS) based on one of the following: (a) Demonstration of a 17p11.2 deletion OR (b) Detection of mutation in RAI1 gene AND is using to treat sleep disturbances related to SMS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For continued use, there is clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to, increase in nighttime sleep, decrease in daytime nap time, improvement in sleep quality).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# HRM Age

## Products Affected

- *amoxapine*
- *clomipramine hcl oral*
- *desipramine hcl oral*
- *doxepin hcl oral capsule*
- *doxepin hcl oral concentrate*
- *imipramine hcl oral*
- *perphenazine-amitriptyline*
- *phenobarbital oral elixir*
- *phenobarbital oral tablet 100 mg, 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg*
- *protriptyline hcl*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Prescriber must acknowledge this is a high risk medication (HRM) (as identified by American Geriatric Society) for individuals greater than 65 and medication benefits outweigh potential risk for this individual.
<b>Age Restrictions</b>	Individuals that are 64 years of age or younger are NOT subject to the prior authorization requirements. Prior Authorization applies to individuals that are 65 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# HRM Age AU

## Products Affected

- *benztropine mesylate oral*
- *cyclobenzaprine hcl oral tablet 10 mg, 5 mg*
- *cyproheptadine hcl oral syrup*
- *digox oral tablet 250 mcg*
- *digoxin injection*
- *digoxin oral tablet 250 mcg*
- DOTTI
- *estradiol transdermal patch twice weekly*
- *estradiol transdermal patch weekly*
- FYAVOLV ORAL TABLET 1-5 MG-MCG
- *guanfacine hcl oral*
- JINTELI
- LYLLANA
- *methyldopa oral tablet 500 mg*
- *norethindrone-eth estradiol*
- *trihexyphenidyl hcl oral solution*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Prescriber must acknowledge this is a high risk medication (HRM) (as identified by American Geriatric Society) for individuals greater than 65 and medication benefits outweigh potential risk for this individual.
<b>Age Restrictions</b>	Individuals that are 64 years of age or younger are NOT subject to the prior authorization requirements. Prior Authorization applies to individuals that are 65 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Human Growth Hormone

## Products Affected

- NORDITROPIN FLEXPRO  
SUBCUTANEOUS SOLUTION PEN-  
INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Initial Requests, For idiopathic GHD, has signs/sym of GHD, GV 2 SD below age-appropriate mean or ht 2.25 SD below age-appropriate mean and A subnormal (SubNL) response (less than 10ng/ml) to 2 GH stim tests OR Neonates with hypoglycemia and clinical/hormone evidence of hypopit and low GH (less than 10ng/ml) OR 2 other pit hormone deficiencies and low IGF-1 OR mbr has cranial irradiation with low IGF1 and normal thyroid tests. Child born SGA (birth wt or length 2 or more SD below the mean for gest age), Child fails to manifest catch up growth by age 4yr (ht 2 or more SD below the mean for age, gender) AND Other causes for SS have been ruled out. Transitioning adolescent: completed linear growth (growth rate of less than 2cm/yr) AND either of the following: A) GH tx has been stopped at least a month and GHD reconfirmed by: 1) idiopathic isolated GHD (SubNL response to 2 GH stim tests OR SubNL response (GH conc of less than 10 ng/mL) to 1 provocative test and low IGF-I/IGFBP-3) OR 2) multiple pit hormone deficiency, (SubNL response to 1 provocative GH test and/or low IGF-I/IGFBP-3 or 3) with cranial irradiation, low IGF with normal thyroid OR B) any of the following: known genetic mutation assoc with def GH production/secretion or Hypothalamic-pit tumor/structural defect or 3 other pit hormone deficiencies. Adult GHD, mbr has GHD in childhd or docmtd hypopit, hypothal dz, surgery, radiation therapy, trauma, or aneurysmal subarachnoid hemorrhage. GHD confirmed/reconfirmed: SubNL response in adults to 2 GH stim tests (GH conc of less than or equal to 5ng/ml when using insulin induced hypoglycemia OR GH conc of less than or equal to 4.1ng/ml when using arginine) OR SubNL response to 1 stim test for adults with hypothalamic or pit dz and 1 pit hormone deficits OR 3 other pit hormone deficiencies.</p>

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	<p>Initial requests for therapy in child: For Reconstructive GH tx, if either mean ht is at least 2.25 but less than 2.5SD below the mean for age, gender and GV is less than the 10th percentile over 1yr OR mean ht is at least 2.5SD below the mean for age, gender for conditions known responsive to GH. For Continuation therapy: in child (including reconstructive tx) when following are met: individual evaluated AND child over 12: an X-ray report with evidence that epiphyses have NOT closed or SMR of less than or eq to 3. Termination for reconstructive use: Epiphyseal fusion has occurred. GH in adults, GHD is reconfirmed as noted above. GH for Adolescents with childhood onset GHD who have completed linear growth.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Humira

## Products Affected

- HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT 40 MG/0.4ML, 40 MG/0.8ML, 80 MG/0.8ML
- HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML
- HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT 80 MG/0.8ML
- HUMIRA-PED $\geq$ 40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PSORIASIS/UVEIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Chronic moderate to severe plaque psoriasis with either of the following: Patient has greater than or equal to 3% of body surface area with plaque psoriasis OR Less than 3% of body surface area with plaque psoriasis involving sensitive areas or areas that significantly impact daily function (such as palms, soles of feet, head/neck, or genitalia) AND agent is used to reduce signs/symptoms OR to induce/maintain clinical response.
<b>Age Restrictions</b>	Individual is 18 years of age or older for all indications except JIA, uveitis, UC, Hidradenitis Suppurativa (HS) and Crohns disease. Individual is 2 years old for JIA and uveitis. Individual is 6 years of age for Crohns disease. Individual is 12 years old for HS. Individual is 5 years of age or older for UC.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For initial use: For RA, mbr has had an inadequate response to MTX titrated to maximally tolerated dose (ACR 2021) OR has a contraindication(CI) to MTX. For Ankylosing Spondylitis (AS), mbr has had an inadequate response to, or is intolerant of, ONE conventional therapy (such as NSAIDs or nonbiologic DMARDs (such as sulfasalazine) OR has a CI to NSAIDs or sulfasalazine. For Crohn's disease, mbr has had an inadequate response to, or is intolerant of, ONE conventional therapy (e.g. systemic corticosteroids, or immunosuppressants) OR has a CI to systemic corticosteroids or thiopurines or MTX. For plaque psoriasis, mbr has had an inadequate response to, or is intolerant of, phototherapy or ONE other systemic therapy (e.g. methotrexate, acitretin, or cyclosporine) OR has a CI to phototherapy, acitretin, cyclosporine, and MTX. For Polyarticular Juvenile Idiopathic Arthritis (PJIA), mbr has had an inadequate response to, or is intolerant of, ONE conventional therapy [nonbiologic DMARDs (such as methotrexate)] (ACR 2011) OR has a CI to MTX. For Ulcerative Colitis (UC), mbr has had an inadequate response to, or is intolerant of, ONE conventional therapy (such as 5-ASA products, systemic corticosteroids, or immunosuppressants [such as thiopurines]) OR has a CI to 5-ASA products or systemic corticosteroids or thiopurines. For uveitis, mbr has chronic, recurrent, treatment-refractory or vision-threatening disease and has had an inadequate response to, or is intolerant of, ONE conventional therapy (such as corticosteroids or immunosuppressants [azathioprine, cyclosporine, or MTX]) OR has a CI to corticosteroids, azathioprine, cyclosporine, and MTX. For chronic, progressive, treatment-refractory Sarcoidosis (Sweiss 2014), mbr has had an inadequate response to, or is intolerant of ONE nonbiologic DMARDs (such as methotrexate or azathioprine) OR has a CI to MTX and azathioprine. For Hidradenitis Suppurativa (Hurley stage II or Hurley stage III disease) AND has had an inadequate response to, or is intolerant of, ONE conventional therapy (such as oral antibiotics) OR has a CI to oral</p>
	<p>antibiotics. For continued use, there is clinically significant improvement or stabilization in clinical signs and symptoms of the disease AND has been receiving and is maintained on a stable dose of adalimumab.</p>
<b>Indications</b>	All Medically-accepted Indications.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Ibrance

---

## Products Affected

- IBRANCE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Breast cancer, HR status and HER2 status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Iclusig

---

## Products Affected

- ICLUSIG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For ALL, Philadelphia chromosome (Ph) status. For CML, T315I status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Idhifa

---

## Products Affected

- IDHIFA ORAL TABLET 100 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Individual has confirmed (written or verbal attestation) isocitrate dehydrogenase-2 (IDH2) mutation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Imbruvica

---

**Products Affected**

- IMBRUVICA ORAL CAPSULE 140 MG, 560 MG  
70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET 420 MG,

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Imkeldi

---

## Products Affected

- *imkeldi*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For CML/ALL Philadelphia chromosome (Ph) status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Increlex

## Products Affected

- INCRELEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For initial treatment of growth failure associated with severe primary IGF-1 deficiency as defined by: Height standard deviation score of less than or equal to -3.0 AND Basal IGF-1 standard deviation score of less than or equal to -3.0 AND normal or elevated growth hormone levels (greater than 10ng/mL on standard GH stimulation tests) are present OR GH gene deletion who have development of neutralizing antibodies to GH.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For Continuation of treatment with Increlex (mecasermin), Final adult height has not been reached.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Inlyta

---

## Products Affected

- INLYTA ORAL TABLET 1 MG, 5 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 YEAR.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Inqovi

---

## Products Affected

- INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Inrebic

---

## Products Affected

- INREBIC

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individual is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Interferons for MS

---

## Products Affected

- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has diagnosis of relapsing multiple sclerosis (RMS) (including clinically isolated syndrome, relapsing-remitting disease or active secondary progressive disease).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Iressa

## Products Affected

- *gefitinib*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For NSCLC, written or verbal attestation is provided to confirm EGFR mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has a diagnosis of recurrent, advanced, or metastatic Non-small cell lung cancer (NSCLC).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Itovebi

---

## Products Affected

- ITOVEBI ORAL TABLET 3 MG, 9 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Breast cancer (defined as IHC 0 or 1+, or IHC 2+/ISH-), hormone receptor (HR) status, human epithelial growth factor receptor 2 (HER2) status, and PIK3CA-mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year.
<b>Other Criteria</b>	Individual has progressed during adjuvant endocrine treatment or within 12 months of completing adjuvant endocrine therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# ITRACONAZOLE

## Products Affected

- *itraconazole oral capsule*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	For fingernail/toenail onychomycosis 12 weeks. For all other indications 1 year.
<b>Other Criteria</b>	For second-line non-onychomycosis indications include tinea infections (including, but limited to tinea versicolor, tinea cruris, tinea corporis, tinea pedis, tinea manuum, and tinea capitis) where the individual has had a trial and inadequate response or intolerance to at least one prior topical therapy: ciclopirox, clotrimazole, ketoconazole, econazole, or nystatin. OR Individual is transitioning from inpatient treatment to an outpatient setting and requires continued therapy for an organism susceptible to itraconazole for a non-onychomycosis use.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# IVIG

---

## Products Affected

- GAMUNEX-C
- OCTAGAM INTRAVENOUS SOLUTION  
1 GM/20ML, 2 GM/20ML, 2.5 GM/50ML,  
30 GM/300ML, 5 GM/100ML

PA Criteria	Criteria Details
Exclusion Criteria	

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Required Medical Information</b>	<p>For INIT Autoimmune (AI) MC blistering dx, when mbr had inadeq response/intolerance/contraindication (CI) to other tx such as steroids/ISx. For INIT AI neutropenia, active INFECT is excluded as cause. For INIT tx of 1 neurologic DZ: A) Lambert-Eaton myasthenic syndrome when having muscle weakness AND dx confirmed w/characteristic electrodiagnostic finding using nerve conduction tests, repetitive nerve stimulation (RNS), exercise testing or single fiber EMG (SFEMG) or presence of AB directed against voltage-gated Ca channels B) For MG and dx confirmed by presence of AB against the ach receptor or muscle specific tk or characteristic ED findings using RNS or SFEMG AND using for exacerbation or acute MG crisis or short-term therapy as ISx tx is taking effect or MAINT therapy of MG when mbr had inadeq response/intolerance/CI to Pyridostigmine, Corticosteroids and Non-steroidal ISx. C) CIDP when muscle weakness or sensory dysfx is caused by neuropathy in more than 1 limb and evidence of demyelinating neuropathy confirmed by EFNS/PNS or AAN guidelines or CSF analysis and other polyneuropathies. D) For MMN, dx is confirmed by EFNS/PNS 2010/AANEM 2003 guidelines. E) Stiff-person synd when mbr had inadeq response/intolerance/CI to other treatments such as benzodiazepines or baclofen. For cont use of above dx A-E, clinically/objective sig improvement in neurological sx on phys exam and cont need is shown by clinical effect. For INIT AE, dx is confirmed by specific autoab assoc with AE and Clinical present inc neuro sx (i.e, memory deficits, seizures, movement disorders, speech disturbances, behav changes, or psych symptoms) and Alternative etiologies of encephalitis syndrome have been ruled out, such as infectious etiologies, other neuro disorders, or other AI conditions.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>Tx of primary (PI) when hx of recur (SI) req ABX tx AND lack of/inadeq resp to immuniz AND no evidence of renal (nephrotic synd) and GI as causes of HGG AND INIT pre-tx total serum IgG below the lower limit of age adj lab ref range or more than 2SD below age adj mean OR tx of SAD when hx of recnt SI req ABX tx AND lack of inadeq respond to pneumococcal antigen AND normal conc IgG, IgA, IgM, and IgG OR for SCID when INIT pre-tx total serum IgG below the lower limit of age adj lab ref range or more than 2SD below age adj mean OR CD3+ T cell less than 300 cells/mm<sup>3</sup> OR presence of maternal T cells in circulation AND no evid of renal and GI as cause of HGG. OR Use for ONE: A) B-cell CLL w/ hx of recur bacterial or active INFECT not respond to AB therapy and HGG w/ total IgG less than 500mg/dL B) MM with 1) hx of clinically sev INFECT or active clinically sev INFECT and HGG or 2) total IgG less than 400mg/dL C) HIV infected children to prevent opport bacterial infection w/HGG (IgG less than 400mg/dL) or recurrent INFECT D) PARVO B19 chronic INFECT and severe anemia assoc w/BM suppression. OR using in context of transplant (TX) for ONE: 1) HSCT 2) Solid organ transplantation (TP) including prior desens for TP for supp of PRA anti-HLA antibody (AB) in ppl with high AB (PRA/cPRA) levels to HLA or in mbr w/hx of high levels of donor-spec AB or TX recip at risk of CMV 3) TX recip exp AB-mediated rej w/donor-spec AB. OR for tx of AI DZ: A) ITP w/either active bleed or PT less than 30,000 mcL B) Fetal alloimmune TCP w/AB to paternal PT antigen in maternal serum and ONE: Prev affected PREG, family hx of maternofetal alloimmune thrombocytopenia (TCP) or fetal blood sample shows TCP C) Isoimmune hemolytic dx of newborn, tx of sev jaundice D) Dermatomyositis (DMM) or polymyositis when mbr had inadeq response/intolerance/CI to other tx, e.g., corticosteroids, non-steroidal IS agents AND Dx confirmed having at least 4 sx: weak trunk/proximal extremities, high serum CK or aldolase levels, unexplainable muscle pain, EMG findings, anti-Jo-1 AB, arthralgia/arthritis w/out joint destruction, sign of systemic inflamm,</p>

PA Criteria	Criteria Details
	e.g., fever/elevated CRP high SED rate or inflamm myositis seen on muscle biopsy AND using for DMM and skin lesions present or E) AI Encephalitis (AE), eval for neoplasm assoc w/AE. For CONT use of AE/AI MC blistering dx/DMM or polymyositis, is clinically sig improv in sym on phys exam and need is demon by clinical effect (i.e, pos response, stable on current dose, or worsening of symp occurs from a dose dec or inc in dose intervals, or prev dc resulted in relapse and Cancer screening continues.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Iwilfin

---

## Products Affected

- IWILFIN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Jadenu

---

## Products Affected

- *deferasirox oral tablet 90 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	For dx non-transfusion-dependent thalassemia (NTDT) syndrome, 10 years of age or older. For dx of chronic iron overload, 2 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Jakafi

---

## Products Affected

- JAKAFI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Jaypirca

---

## Products Affected

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual is using as a single agent. Written or verbal attestation is provided for confirmation of mutations where applicable based on use/diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Kalydeco

## Products Affected

- KALYDECO ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For initial use, individual has a diagnosis of cystic fibrosis (CF) AND has mutation-positive result in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and the mutation type is provided and responsive to Kaldeco.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For continuation requests, there is clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to improvement in FEV1, decrease in pulmonary exacerbations, improvement in BMI or improvement of respiratory symptoms [cough, sputum production, difficulty breathing]).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Kisqali

## Products Affected

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)
- KISQALI FEMARA (200 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Breast cancer, hormone receptor (HR) status, human epithelial growth factor receptor 2 (HER2) status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Korlym

## Products Affected

- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of Cushings has been verified by, or in consultation with, a board-certified endocrinologist who has reviewed and verified the test results (including but not limited to: 24-hour urinary free cortisol (UFC) test, Dexamethasone suppression test (DST), Late-night salivary cortisol (LNSC) test) that are indicative of a positive test.
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial: 6 months. Continuation: 1 Year.
<b>Other Criteria</b>	Initial therapy: Individual is not a candidate for surgery that is expected to correct the cause of endogenous Cushings Syndrome OR disease persists or recurs following surgery intended to correct the cause of endogenous Cushings Syndrome. For continuation of therapy: Individual continues to meet the initial request approval criteria AND has experienced an improvement in or stabilization of glucose control as assessed by fasting serum glucose test, oral glucose tolerance test or hemoglobin A1c test.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Koselugo

---

## Products Affected

- KOSELUGO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Krazati

---

## Products Affected

- KRAZATI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For NSCLC and Colon/Rectal cancer, KRAS G12C mutation status.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No



# Kuvan

## Products Affected

- *sapropterin dihydrochloride oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For initial requests, Individual has Dx of Hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4) responsive PKU. For continued use, has Dx of Hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4) responsive PKU AND. There is a positive response to therapy as evidenced by reduction in blood PHE levels from baseline.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial 8 weeks, 1 year for continuation
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Lazcluze

---

## Products Affected

- LAZCLUZE ORAL TABLET 240 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For NSCLC, EGFR mutation status.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# Lenvima

## Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Letairis

## Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For initial use, Individual has diagnosis of Pulmonary Arterial Hypertension World Health Organization (WHO) Group 1. Individual has a right heart catheterization showing all of the following: (a) Mean pulmonary artery pressure (mPAP) greater than or equal to 25 mm Hg at rest (b) Pulmonary capillary wedge pressure (PCWP), mean pulmonary artery wedge pressure (PAWP), left atrial pressure, or left ventricular end-diastolic pressure (LVEDP) less than or equal to 15 mm Hg (c) Pulmonary vascular resistance (PVR) greater than 3 Wood units. AND Individual has WHO functional class II- IV symptoms.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For continuation use, there is clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to improvement in walk distance, dyspnea and/or functional class).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Lidocaine 4

---

## Products Affected

- *lidocaine hcl external solution*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual is using for anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Lidoderm Patch

---

## Products Affected

- *lidocaine external patch 5 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Livtency

---

## Products Affected

- LIVTENCITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual is using to treat cytomegalovirus (CMV) infection or disease AND is a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) recipient AND is refractory to treatment with ganciclovir, valganciclovir, cidofovir or foscarnet.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Lonsurf

---

## Products Affected

- LONSURF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Lorbrena

---

## Products Affected

- LORBRENA ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis, ALK status, ROS1 status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Lotronex

## Products Affected

- *alosetron hcl*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual is a Female with Severe diarrhea-predominant Irritable Bowel Syndrome (IBS) defined as including diarrhea and 1 or more of the following: Frequent and severe abdominal pain/discomfort, Frequent bowel urgency or fecal incontinence, Disability or restriction of daily activities due to IBS. Member is female AND Member has chronic symptoms of IBS that have persisted for 6 months or longer AND does not have an anatomic or biochemical abnormality of the gastrointestinal tract.
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has a trial and inadequate response or intolerance TWO (2) of the following medications: (a) Loperamide (b) antispasmodics (for example, dicyclomine), or (c) tricyclic antidepressants (AGA 2021).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Lumakras

---

## Products Affected

- LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For NSCLC, KRAS G12C mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For NSCLC, individual has confirmed (written or verbal) disease progression after one or more prior lines of systemic therapy and using as monotherapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Lupron Depot

## Products Affected

- *leuprolide acetate (3 month)*
- LUPRON DEPOT (1-MONTH)  
INTRAMUSCULAR KIT 3.75 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>For Prostate cancer: Clinically localized dz with intermediate (T2b to T2c cancer, Gleason score of 7/Gleason grade group 2-3, or prostate specific antigen (PSA) value of 10-20 ng/mL) or higher risk of recurrence as neoadjuvant therapy with radiation therapy or cryosurgery OR Other advanced, recurrent, or metastatic disease.</p> <p>For Gynecology Uses: Initial treatment/retreatment of endometriosis OR Preoperative tx as adjunct to surgical tx of uterine fibroids (leiomyoma uteri), May be used to reduce size of fibroids to allow for a vaginal procedure, prior to surgical tx (myomectomy or hysterectomy) in patients with confirmed anemia (Letheby et al. 2001, 2017). To induce amenorrhea in women (such as but not limited to menstruating women diagnosed with severe thrombocytopenia or aplastic anemia). Using for endometrial thinning prior to endometrial ablation for dysfunctional uterine bleeding. For Endocrine Uses: central Precocious puberty, defined as beginning of secondary sexual characteristics before age 8 in girls and before age 9 in boys and dx has been confirmed (written or verbal) by one of the following: pubertal response to a GnRH agonist test OR A pubertal level of:(1) a third generation LH assay OR (2) pediatric LH assay OR (3) ultra-sensitive LH assay OR (4) assay that can detect levels less than 0.2 AND has been confirmed (written or verbal) by assessment of bone age versus chronological age. For Ovarian Cancer (including fallopian tube cancer and primary peritoneal cancer): Hormonal therapy for clinical relapse in individuals with stage II-IV granulosa cell tumors or Hormonal therapy for treatment of epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer as a single agent for persistent dz or recurrence.</p>

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For Gender Dysphoria/incongruence (Coleman 2022) mbr has experienced puberty to at least Tanner stage 2 (Hembree 2017, Coleman 2022)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Lupron Kit IR

## Products Affected

- *leuprolide acetate injection*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Prostate cancer: Clinically localized disease with intermediate (T2b to T2c cancer, Gleason score of 7/Gleason grade group 2-3, or prostate specific antigen (PSA) value of 10-20 ng/mL) or higher risk of recurrence as neoadjuvant therapy with radiation therapy or cryosurgery OR Other advanced, recurrent, or metastatic disease.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Lynparza

---

## Products Affected

- LYNPARZA ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Ovarian, Breast cancer, Prostate, and Pancreatic cancer, BRCA mutation status. For mCRPC, germline or somatic homologous recombination repair (HRR) status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 YEAR.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Lytgobi

---

## Products Affected

- LYTGOBI (12 MG DAILY DOSE)
- LYTGOBI (16 MG DAILY DOSE)
- LYTGOBI (20 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For intrahepatic cholangiocarcinoma, FGF/FGFR2 mutation status.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	Individual is using as a single agent
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Megace Suspension HRM

---

## Products Affected

- *megestrol acetate oral suspension 40 mg/ml, 400 mg/10ml, 800 mg/20ml*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual is using for the treatment of cachexia, or unexplained weight loss in individuals with HIV/AIDS. Prescriber must acknowledge this is a high risk medication (HRM) [as identified by American Geriatric Society] for individuals greater than 65 and medication benefits outweigh potential risk for this individual.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Megace Tabs HRM

---

## Products Affected

- *megestrol acetate oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Prescriber must acknowledge this is a high risk medication (HRM) [as identified by American Geriatric Society] for individuals greater than 65 and medication benefits outweigh potential risk for this individual.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 YEAR.
<b>Other Criteria</b>	Individual has advanced, inoperable, recurrent breast cancer and using for palliative management. Individual has endometrial/uterine cancer and is using for palliative management.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Mekinist

---

## Products Affected

- MEKINIST ORAL SOLUTION RECONSTITUTED
- MEKINIST ORAL TABLET 0.5 MG, 2 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Melanoma, NSCLC, ATC, Solid Tumors, and Glioma, BRAF V600 mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Mektovi

## Products Affected

- MEKTOVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Melanoma and NSCLC, BRAF V600 mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For NSCLC (NCT03915951), individual is treatment naive or had previously received 1 prior line of systemic therapy in the advanced/metastatic setting AND has not received prior treatment with any BRAF inhibitor (e.g. dabrafenib, vemurafenib) or MEK inhibitor (cobimetinib, selumetinib).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Mepron

---

## Products Affected

- *atovaquone oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Intolerance to trimethoprim-sulfamethoxazole (TMP-SMX)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Methylphenidate

## Products Affected

- *methylphenidate hcl er oral tablet extended release*
- *methylphenidate hcl oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual is using for Attention Deficit Hyperactivity Disorder/Attention Deficit Disorder (ADHD/ADD) or Narcolepsy.
<b>Age Restrictions</b>	For ADHD, 6 years of age and older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Mounjaro

## Products Affected

- MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Individual is using for weight loss.
<b>Required Medical Information</b>	Documentation (written) has been provided for diagnosis. Attestation has been provided that diagnosis has been verified by history of: (A) Hemoglobin A1c (A1C) greater than or equal to 6.5% OR (B) Fasting Plasma Glucose (FPG) greater than or equal to 126 mg/dl (after fasting for at least 8 hours) OR (C) 2 hour plasma glucose greater than or equal to 200mg/dl as part of an oral glucose tolerance test (75g oral glucose after fasting for at least 8 hours) OR (D) Symptoms of hyperglycemia (including polyuria, polydipsia, polyphagia) or hyperglycemic crisis and a random plasma glucose greater than or equal to 200 mg/dl.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For Type 2 Diabetes.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Mozobil

## Products Affected

- *plerixafor*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months.
<b>Other Criteria</b>	Individual may use a maximum of up to four consecutive doses of plerixafor (Mozobil) injections per cycle for up to 2 cycles. Individual is using Mozobil (plerixafor) for autologous hematopoietic stem cell (HSC) mobilization as part of the development of an FDA-approved ex vivo gene therapy (e.g. Zynteglo).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# MSB Antipsychotics

## Products Affected

- COBENFY
- COBENFY STARTER PACK
- FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG
- FANAPT TITRATION PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has had a trial of and inadequate response or intolerance to ONE of the following generic oral atypical antipsychotic: Aripiprazole, Asenapine tablets, Lurasidone, Olanzapine, Paliperidone ER, Quetiapine IR, Risperidone, or Ziprasidone OR the preferred generics are not FDA approved and do not have an accepted off-label use for the prescribed indication and the non-preferred agent does.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Namenda Line

---

## Products Affected

- *memantine hcl er*
- *memantine hcl oral solution 2 mg/ml*
- *memantine hcl oral tablet 10 mg, 5 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individuals that are 50 years of age or older are NOT subject to the prior authorization requirements. Prior Authorization applies to individuals that are 49 years of age or younger.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Individual has a diagnosis of moderate to severe dementia of the Alzheimers type.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Nayzilam

---

## Products Affected

- NAYZILAM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Individual is 12 years of age or older.
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Nerlynx

---

## Products Affected

- NERLYNX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has HER2- overexpressed/amplified confirmed by one of the following: (A) Immunohistochemistry (IHC) is 3+ or (B) In situ hybridization (ISH) positive.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Nexavar

---

## Products Affected

- *sorafenib tosylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Ninlaro

## Products Affected

- NINLARO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year.
<b>Other Criteria</b>	For multiple myeloma, individual received at least two prior therapies, including immunomodulatory agent and a proteasome inhibitor AND demonstrated disease progression on or within 60 days of completion therapy AND Ninlaro is given as part of a treatment regimen containing dexamethasone and pomalidomide.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Northera

## Products Affected

- *droxidopa oral capsule 100 mg, 200 mg, 300 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial: 3 months. Continuation: 1 year
<b>Other Criteria</b>	For initial use, individual has had a trial and inadequate response or intolerance to one prior symptomatic nOH pharmacologic therapy (which may include midodrine or fludrocortisone [AHFS]). For continued use, individual has experienced a positive clinical response with droxidopa use (e.g., sustained decrease in dizziness).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Noxafil

---

## Products Affected

- *posaconazole oral tablet delayed release*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For an individual who requires continued therapy for an organism susceptible to Posaconazole who is transitioning from inpatient treatment to an outpatient setting.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# NP LA Opioid

---

## Products Affected

- *methadone hcl oral tablet*
- *morphine sulfate er oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial 3 months. Maintenance 6 months. Cancer Pain/Terminal Dx or Palliative Care 1 Year.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For initial use, Individual has one of the following: (a) Diagnosis of cancer related pain and/or is actively undergoing cancer therapy (provide cancer diagnosis) OR (b) Diagnosis of terminal illness and is receiving palliative/end-of-life care (provide terminal diagnosis) OR Individual has pain severe enough to require daily, around-the-clock, long term opioid treatment (provide diagnosis) AND Individual has one of the following: (a) An inadequate response to ONE alternative treatment options, such as but not limited to non-opioid analgesics and immediate-release opioids OR (b) Alternative treatment options would otherwise be inadequate to provide sufficient management of pain OR (c) Individual has contraindications to non-opioid analgesics (such as NSAID use in individuals with active ulcer condition/gastrointestinal bleeding, renal failure) AND for initial therapy, individual is not opioid naive as noted by the following: (a) Individual is currently using a short-acting opioid analgesic, including use of opioid analgesia as an inpatient for post-surgical pain OR (b) Individual is transitioning from one long-acting opioid analgesic to another long-acting opioid analgesic. For continued use, (I) individual has a diagnosis of cancer related pain and/or is actively undergoing cancer therapy (provide cancer diagnosis) OR (II) diagnosis of terminal illness and is receiving palliative/end-of-life care (provide terminal diagnosis) OR (III) Individual has pain severe enough to require daily, around-the-clock, long term opioid treatment (provide diagnosis) AND Attestation (verbal or written) that long-acting opioid therapy has provided meaningful improvement in pain and/or function compared to baseline AND Prescriber has consulted individual regarding risks of opioid therapy AND clear treatment goals have been defined and outline as part of overall plan.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Nubeqa

## Products Affected

- NUBEQA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) Individual has Metastatic hormone-sensitive prostate cancer (mHSPC) OR (2) Individual has a diagnosis of non-metastatic castration resistant prostate cancer (nmCRPC) AND has a PSA doubling time (PSADT) less than or equal to 10 months AND (3) One of the following: (a) individual is concomitantly receiving a gonadotropin-releasing hormone (GnRH) analog [e.g. Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (Degarelix)] OR (b) Has had a bilateral orchiectomy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Nuedexta

## Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual is using for the treatment of amyotrophic lateral sclerosis (ALS) (Orphan indication) OR Individual has a diagnosis of pseudobulbar affect (PBA) AND has a concomitant diagnosis with an unrelated neurologic disease or injury [amyotrophic lateral sclerosis (AAN 2020, Piro et al. 2010), multiple sclerosis (AAN 2019, Piro et al, 2010), stroke (2016 AHA/ASA)].
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Nuplazid

## Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial:3 months, Maintenance: 1 Year
<b>Other Criteria</b>	Initial therapy: Individual has a diagnosis of Parkinsons disease AND Symptoms of psychosis developed after the PD diagnosis AND Symptoms of psychosis include at least one of the following: (1) Visual hallucinations, (2) Auditory hallucination OR (3) Delusions AND Symptoms have been present for at least one month AND Individual has experienced symptoms at least once weekly. Psychiatric symptoms cannot be attributed to disorders such as schizophrenia, schizoaffective disorder, delusional disorder, or mood disorder with psychotic features, or a general medical condition including delirium. For continued therapy, the individual has had a reduction in symptoms of psychosis compared to baseline.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Nurtec

---

## Products Affected

- NURTEC

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For the acute treatment of migraine headaches, Individual has had a trial of and inadequate response or intolerance to two oral triptans (AHS 2021) OR has one of the following cardiovascular or non-coronary vascular contraindications to use of triptans: (a) Ischemic coronary artery disease (CAD) including angina pectoris, history of myocardial infarction, documented silent ischemia, coronary artery vasospasm (including Prinzmetal's angina) or (b) History of stroke or transient ischemic attack (TIA) or (c) Peripheral vascular disease or (d) Ischemic bowel disease or (e) Uncontrolled hypertension.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For initial use in prevention of episodic migraine headaches, mbr has a dx of episodic migraine defined as at least 4 and fewer than 15 migraine days per month and fewer than 15 HA days per month on average during the previous 3 month period (ICHD-3) AND is using agent for migraine prophylaxis. AND If mbr is also currently using botulinum toxin for prophylaxis and is going to be using Nurtec ODT and botulinum toxin together (i.e., not switching from one agent to another), the following must apply: (1) Individual has had a reduction in the overall number of migraine days or reduction in number of severe migraine days per month with botulinum toxin use AND (2) continues to experience a significant number of migraine headache days or severe migraine days per month requiring additional therapy for migraine prevention. For Continued use for migraine prophylaxis, mbr has a reduction in the overall number of migraine days or reduction in number of severe migraine days per month AND has obtained clinical benefit deemed significant by individual or prescriber including any of the following (AHS 2021): (a) 50% reduction in frequency of days with headache or migraine OR (b) Significant decrease in attack duration OR (c) Significant decrease in attack severity OR (d) Improved response to acute treatment OR (e) Reduction in migraine-related disability and improvements in functioning in important areas of life OR (f) Improvements in health related quality of life and reduction in psychological stress due to migraine AND If individual is using concurrently with botulinum toxin for migraine prophylaxis, the following must apply: Individual has had further reduction in the overall number of migraine days or reduction in number of severe migraine days per month compared to monotherapy with botulinum toxin.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Nuvigil

## Products Affected

- *armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>For Narcolepsy type 1: defined by the presence of daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months and at least one of the following: 1. Clear cataplexy (defined as more than one episode of generally brief usually bilaterally symmetrical, sudden loss of muscle tone with retained consciousness) AND 2. Multiple Sleep Latency Test (MSLT) showing one of the following: a. Mean sleep latency of less than 8 minutes with evidence of two sleep-onset rapid eye movement periods (SOREMPs) (ICSD-3, 2014) OR b. MSL less than 8min of at least one SOREMP on MSLT and a SOREMP (less than 15 minutes) on the preceding overnight polysomnography (PSG) OR 3. Cerebrospinal fluid hypocretin-1 deficiency (less than 100pg/mL or less than one-third of the normative values with the same standardized assay). For Narcolepsy type 2: defined by 1. Multiple sleep latency test (MSLT) with one of the following: a. Mean sleep latency of less than 8 minutes with and evidence of two sleep-onset rapid eye movement periods (SOREMPs) ICSD-3, 2014) OR b. MSL less than 8min of at least one SOREMP on MSLT and a SOREMP (less than 15 minutes) on the preceding overnight polysomnography (PSG) AND 2. The absence of cataplexy AND 3. Exclusion of alternative causes of excessive daytime sleepiness by history, physical exam and Polysomnography.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	<p>For obstructive sleep apnea/hypopnea syndrome objectively verified by polysomnography (PSG) or home testing with portable monitor showing one of the following (AASM 2017, ICDS-3): 1. Greater than 15 obstructive events (defined as apneas, hypopneas plus respiratory event related arousal) per hour of sleep OR 2. Greater than 5 obstructive events per hour of sleep and individual reports any of the following: a. Unintentional sleep episodes during wakefulness or b. Daytime sleepiness or c. Unrefreshing sleep or d. Fatigue or e. Insomnia or f. Waking up breath holding, gasping or choking or g. Bed partner describing loud snoring, breathing interruptions or both or h. Presence of comorbid conditions including hypertension, mood disorder, cognitive dysfunction, coronary artery disease, stroke, congestive heart failure, atrial fibrillation or type 2 diabetes mellitus AND 3. Has an Epworth Sleepiness Scale score greater than or equal to 10. For Shift-Work Sleep Disorder (SWSD) defined by all of the following: 1. No other medical disorder or mental disorder accounts for the symptoms AND 2. Symptoms do not meet criteria for any other sleep disorder (i.e. jet lag) AND 3. Symptoms have occurred for at least 3 months, AND 4. Individual has one of the following: a. Individual has excessive sleepiness or insomnia associated with a work period that occurs during the usual sleep phase OR b. Polysomnography demonstrates loss of a normal sleep-wake pattern (such as, disturbed chronobiological rhythmicity).</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Octreotide Line

## Products Affected

- *octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml*
- *octreotide acetate subcutaneous solution prefilled syringe 100 mcg/ml, 50 mcg/ml*
- SANDOSTATIN LAR DEPOT
- *octreotide acetate intramuscular*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of acromegaly has been confirmed by, or in consultation with, a board-certified endocrinologist who has reviewed and verified the test results (such as but not limited to: Insulin-like Growth Factor 1 levels, Oral Glucose Tolerance Test with associated Growth Hormone (GH) levels) that are indicative of a positive test.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Odomzo

---

## Products Affected

- ODOMZO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Ofev

## Products Affected

- OFEV ORAL CAPSULE 150 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>For Initial: dx of idiopathic pulmonary fibrosis (IPF) is demonstrated by (Raghu 2018): Exclusion of other known causes of interstitial lung disease (ILD) such as domestic and occupational environmental exposures, connective tissue disease, and drug toxicity AND High resolution computed tomography (HRCT) with or without lung tissue sampling AND Individual has pulmonary function tests within prior 60 days demonstrating Forced Vital Capacity (% FVC) greater than or equal to 50% AND has had a trial and inadequate response or intolerance to pirfenidone. For dx systemic sclerosis-associated interstitial lung disease (SSc-ILD), mbr has been demonstrated by chest high resolution computed tomography (HRCT) scan showing fibrosis affecting greater than or equal to 10% of the lungs and individual has pulmonary function tests within prior 60 days demonstrating Forced Vital Capacity (%FVC) greater than or equal to 40%. For dx of chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype, mbr has been demonstrated by chest (HRCT) scan showing fibrosis affecting greater than or equal to 10% of the lungs AND progressive disease has been demonstrated by one of the following within the last 24 months while on treatment: (a) FVC decline of greater than or equal to 10% OR (b) 2 of the following: (1) FVC decline greater than or equal to 5% and less than 10% or (2) Worsening respiratory symptoms or (3) Increased fibrosis on HRCT AND individual has pulmonary function tests within prior 60 days demonstrating FVC greater than or equal to 45%.</p>
<b>Age Restrictions</b>	

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For Continuation, there is clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to decreased frequency of exacerbations, slowed rate of FVC decline or improvement in respiratory symptom burden).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ogsiveo

---

## Products Affected

- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Individual has an ECOG performance status of 0-2.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# Ojemda

---

## Products Affected

- OJEMDA ORAL SUSPENSION RECONSTITUTED
- OJEMDA ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For LGG, BRAF fusion or rearrangement, or BRAF V600 mutation status.
<b>Age Restrictions</b>	Individual is 6 months of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Ojjaara

---

## Products Affected

- OJJAARA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Individual has hemoglobin less than 10 g/dL (NCT04173494, NCT01969838).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# Onfi

## Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet 10 mg, 20 mg*
- SYMPAZAN ORAL FILM 10 MG, 20 MG, 5 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis (all ages) and if over 65 years of age or older, Prescriber must acknowledge this is a high risk medication (HRM) [as identified by American Geriatric Society] and medication benefits outweigh potential risk for this individual.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has had a trial of and inadequate response or intolerance to ONE of the following preferred agents: Carbamazepine, Clonazepam/ODT, Clorazepate, Diazepam, Divalproex, Ethosuximide, Felbamate, Gabapentin, Lacosamide, Lamotrigine IR, Levetiracetam IR, Oxcarbazepine, Phenytoin, Primidone, Tiagabine, Topiramate IR, Valproate sodium, Valproic acid, Zonisamide OR the preferred agent is not FDA-approved for the prescribed indication.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Onureg

---

## Products Affected

- ONUREG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has a diagnosis of acute myeloid leukemia (AML), including de novo AML and AML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia (NCT01757535) AND is used as a single agent.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Opsumit

## Products Affected

- OPSUMIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For initial requests, Individual has diagnosis of Pulmonary Arterial Hypertension World Health Organization (WHO) Group 1. Individual has a right heart catheterization showing all of the following: (a) Mean pulmonary artery pressure (mPAP) greater than or equal to 25 mm Hg at rest (b) Pulmonary capillary wedge pressure (PCWP), mean pulmonary artery wedge pressure (PAWP), left atrial pressure, or left ventricular end-diastolic pressure (LVEDP) less than or equal to 15 mm Hg (c) Pulmonary vascular resistance (PVR) greater than 3 Wood units. AND Individual has WHO functional class II- IV symptoms.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual is using for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) OR Individual is using for the treatment of Fontan-Palliated patients. For continuation therapy, there is clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to improvement in walk distance, dyspnea and/or functional class).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Orfadin

---

## Products Affected

- *nitisinone*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For initial requests, Individuals plasma tyrosine level is maintained below 500 micromol/L to reduce risk of ocular symptoms, developmental delay, or hyperkeratotic plaques.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Orgovyx

## Products Affected

- ORGOVYX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For initial therapy, Individual presents with ONE of the following disease state presentations: (a) Evidence of biochemical (PSA) or clinical relapse following local primary intervention with curative intent, such as surgery, radiation therapy, cryotherapy, or high-frequency ultrasound and not a candidate for salvage treatment by surgery OR (b) Newly diagnosed androgen-sensitive metastatic disease OR (c) Advanced localized disease unlikely to be cured by local primary intervention with either surgery or radiation with curative intent. AND is using as androgen deprivation therapy AND is using as a single agent.
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial and Continuation 6 months.
<b>Other Criteria</b>	For continuation therapy, individual does not show evidence of progressive disease while on therapy AND has serum testosterone level less than 50 ng/dL.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Orkambi

## Products Affected

- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For initial use, individual has a diagnosis of cystic fibrosis (CF) AND mutation testing demonstrates the individual has two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
<b>Age Restrictions</b>	Individual is 1 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For continuation requests, there is clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to improvement in FEV1, decrease in pulmonary exacerbations, improvement in BMI or improvement of respiratory symptoms [cough, sputum production, difficulty breathing]).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Orserdu

---

## Products Affected

- ORSERDU ORAL TABLET 345 MG, 86 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Individual is using as a single agent.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Otezla

## Products Affected

- OTEZLA ORAL TABLET
- OTEZLA ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For pediatric Ps, Individual has chronic moderate to severe (that is, extensive or disabling) plaque Ps with either of the following (AAD 2020): (a) Plaque Ps involving greater than three percent (3%) body surface area (BSA) OR (b) Plaque Ps involving less than three percent (3%) BSA involving sensitive areas or areas that significantly impact daily function (such as palms, soles of feet, head/neck, or genitalia).
<b>Age Restrictions</b>	For pediatric Ps, individual is 6 to 17 years of age. All other indications, Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For Initial use in: Psoriatic Arthritis (PsA), Individual has had an inadequate response to, or is intolerant of ONE conventional therapy [nonbiologic DMARDS (such as methotrexate, sulfasalazine, cyclosporine, or leflunomide)] OR has a contraindication to methotrexate, sulfasalazine, cyclosporine, and leflunomide. For plaque psoriasis (Ps), Individual has had an inadequate response to, or is intolerant of phototherapy or other systemic therapy (such as acitretin, cyclosporine or methotrexate) OR has a contraindication to methotrexate, sulfasalazine, cyclosporine, and leflunomide OR individual had an inadequate response to, or is intolerant of ONE, or has a contraindication to ALL of the following topical therapies for psoriasis (Gold 2022): Medium to high potency topical steroid Tazarotene, Vitamin D analogs (calcitriol, calcipotriene, or calcipotriene/betamethasone combination agents), Topical calcineurin inhibitors (tacrolimus or pimecrolimus), Anthralin. For pediatric Ps, member weighing at least 20 kg AND has had an inadequate response to or is intolerant of phototherapy or other systemic therapy (such as acitretin, cyclosporine, or methotrexate) OR has a contraindication to phototherapy, acitretin, cyclosporine, and methotrexate. For Behcets disease, Individual has had an inadequate response to, or is intolerant of ONE conventional therapy [such as topical or systemic corticosteroid, immunosuppressants, colchicine, or NSAIDs] OR has as contraindication to ALL conventional therapy [corticosteroids, immunosuppressants, colchicine, NSAIDs]. For continuation, individual has been receiving and is maintained on a stable dose of Otezla AND there is clinically significant improvement or stabilization in clinical signs and symptoms of disease.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Oxandrin

---

## Products Affected

- *oxandrolone oral tablet 10 mg, 2.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# Pemazyre

## Products Affected

- PEMAZYRE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) OR unresectable locally advanced, or metastatic cholangiocarcinoma AND using as monotherapy AND has confirmed disease progression (written or verbal) after one or more prior lines of systemic therapy. Written or verbal attestation is provided for confirmation of mutations where applicable based on use/diagnosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Piqray

---

## Products Affected

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Breast cancer, hormone receptor (HR) status, human epithelial growth factor receptor 2 (HER2) status, and PIK3CA-mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Pomalyst

---

## Products Affected

- POMALYST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Prevymis

## Products Affected

- PREVYMIS ORAL PACKET
- PREVYMIS ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For allogeneic hematopoietic stem cell transplant (HSCT) recipient, individual is CMV-seropositive and is using to prevent CMV infection or disease AND therapy will be initiated between Day 0 and Day 28 post-transplantation. For kidney transplant recipient, individual is CMV-seronegative and donor is CMV-seropositive AND is using to prevent CMV disease AND therapy will be initiated between Day 0 and Day 7 post-transplantation.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Prolia

## Products Affected

- PROLIA SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Initial requests, Osteoporosis is defined as a BMD T-Score in the spine, femoral neck, total hip or distal 1/3 of the radius of less than or equal to -2.5 as compared to a young-adult reference population OR a clinical diagnosis based on history of a low trauma fracture (fragility fracture). Glucocorticoid-induced osteoporosis defined as a bone mineral density (BMD) T score in the spine, femoral neck, total hip or distal 1/3 of the radius of less than or equal to -2.5 as compared to a young-adult reference population OR a clinical diagnosis based on history of a low trauma fracture (fragility fracture) and is initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5mg or greater of prednisone and expected to remain on glucocorticoids for a least 6 months.
<b>Age Restrictions</b>	For Osteoporosis 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	For Initial use: For osteoporosis/ glucocorticoid-induced osteoporosis treatment, individual has had at least ONE osteoporotic (minimal trauma) fracture OR has two or more risk factors for osteoporotic fracture OR Individual has failed or is intolerant to or has a medical contraindication to other available osteoporosis therapies (such as, bisphosphonates). For male receiving androgen deprivation therapy for non- metastatic prostate cancer, individual has had at least ONE osteoporotic (minimal trauma) fracture OR has one or more additional risk factors for osteoporotic fracture. Individual is a postmenopausal (natural or induced) female receiving adjuvant aromatase inhibitor therapy for the treatment of breast cancer. For continuation requests, there is clinically significant response to therapy (including but not limited to confirmation of no new fractures or reduction of fractures, or no worsening vertebral fractures, or no clinically significant adverse reaction) AND IF individual has been on therapy greater than or equal to 24 months of treatment, a repeat BMD demonstrates a stable or increase in BMD.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Promacta

---

## Products Affected

- PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Initial: 6 months. Continuation: 1 Year.

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For initial therapy: 1) Diagnosis of chronic immune (idiopathic) thrombocytopenia (ITP) AND individual has platelet count of less than 30 x 10<sup>9</sup>/L or active bleeding (ASH, 2011. Hicks et al., 2014) AND has had a prior trial and insufficient response to one of the following: a) corticosteroids OR b) immunoglobulins [for example, intravenous, anti-D] or c) splenectomy OR 2) Diagnosis of severe aplastic anemia AND individual has a platelet count of less than or equal to 30 x 10<sup>9</sup>/L (Olmes et al., 2012.Desmond et al., 2014) AND individual has had a prior trial and insufficient response to an immunosuppressive therapy [such as, anti-thymocyte globulin (ATG)] OR 3) individual is using as first-line treatment in combination with standard immunosuppressive therapy 4) Treatment of thrombocytopenia in individual with hepatitis C AND individual has thrombocytopenia that prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. For continuation therapy, for ITP, severe aplastic anemia or thrombocytopenia in individuals with Hep C, individual has demonstrated a response to therapy as evidenced by increased platelet counts AND to maintain an adequate platelet count (50-200 x 10<sup>9</sup>/L) to decrease the risk of bleeding OR for MDS, individual has demonstrated a clinically significant response to therapy, such as an increase in platelet counts, decrease in bleeding events, or reduction in need for platelet transfusions .</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Protopic

## Products Affected

- *tacrolimus external ointment 0.1 %*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Individual is using as second-line therapy for moderate to severe atopic dermatitis AND has had a trial of and inadequate response or intolerance to one topical prescription strength corticosteroid.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Purixan

---

## Products Affected

- PURIXAN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Qinlock

---

## Products Affected

- QINLOCK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	Individual is using as a single agent AND has a ECOG performance status of 0-2.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# quinine

---

## Products Affected

- *quinine sulfate oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Treatment or prevention of nocturnal recumbency leg muscle cramps or other related conditions including but not limited to: Leg cramps, muscle cramps, myoclonus, Periodic Movements of Sleep, Periodic Limb Movements of Sleep (PLMS), Restless Leg Syndrome (RLS).
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.



PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>Individual has been diagnosed with uncomplicated malaria caused by one of the following: Plasmodium falciparum known or suspected to be resistant to chloroquine (CDC) OR chloroquine-resistant Plasmodium vivax (CDC) OR an unidentified plasmodial species known or suspected to be resistant to chloroquine (CDC) OR Chloroquine-resistant Plasmodium ovale (CDC) OR Chloroquine-sensitive Plasmodium malariae (CDC) OR Chloroquine-sensitive Plasmodium knowlesi (CDC) OR Chloroquine-sensitive Plasmodium falciparum, Plasmodium vivax or Plasmodium ovale AND one of the following (CDC): (i.) Individual is pregnant OR (ii.) Chloroquine and hydroxychloroquine are not available. Individual is using as interim treatment for severe malaria until intravenous artesunate is available (AHFS, CDC) or using as follow-on treatment after intravenous artesunate. Individual has a diagnosis of been diagnosed with babesiosis caused by Babesia microti and treatment is in conjunction with intravenous or oral clindamycin (AHFS, DrugPoints B IIa).</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ranexa

---

## Products Affected

- *ranolazine er*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For dx chronic angina, individual has had a trial and inadequate response or intolerance to one of the following formulary agents (ACCF/AHA 2012): (a) Beta-blocker OR (b) Calcium-channel blocker OR (c) Long-acting nitrate.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Reclast

---

## Products Affected

- *zoledronic acid intravenous solution 5 mg/100ml*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Repatha

---

## Products Affected

- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Retevmo

## Products Affected

- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For NSCLC, MTC, Thyroid cancer, Solid Tumors, written or verbal attestation is provided for RET mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Revatio

## Products Affected

- *sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Individuals requesting for the treatment of erectile dysfunction.
<b>Required Medical Information</b>	For initial requests, individual has diagnosis of Pulmonary Arterial Hypertension in adults World Health Organization (WHO) Group I AND Individual has a right heart catheterization showing all of the following: (a) Mean pulmonary artery pressure (mPAP) greater than or equal to 25 mm Hg at rest (b) Pulmonary capillary wedge pressure (PCWP), mean pulmonary artery wedge pressure (PAWP), left atrial pressure, or left ventricular end-diastolic pressure (LVEDP) less than or equal to 15 mm Hg (c) Pulmonary vascular resistance (PVR) greater than 3 Wood units AND Individual has WHO functional class II- IV symptoms.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For continuation requests of PAH for adults, there is clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to improvement in walk distance, dyspnea and/or functional class).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Revlimid

## Products Affected

- *lenalidomide oral capsule 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For MDS individual has deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Revuforj

---

## Products Affected

- REVUFORJ ORAL TABLET 110 MG, 160 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For Leukemia, KMT2A status.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Rezlidhia

---

## Products Affected

- REZLIDHIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has the applicable mutations based on use/diagnosis. Individual has an ECOG performance status of 0- 2.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For Continued use, there is confirmation of clinically significant improvement (e.g. no disease progression) or stabilization of disease.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Rezurock

---

## Products Affected

- REZUROCK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individual is 12 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For cGVHD after failure of at least two prior lines of systemic therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Rinvoq

---

## Products Affected

- RINVOQ
- RINVOQ LQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	For RA, CD, UC, AS, NR-axSpA, and PsA, individual is 18 years of age or older. For Atopic Dermatitis, individual is 12 years of age or older. For PJIA, individual is 2 years of age or older. For Pediatric PsA, individual is 2 to 17 years of age.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For initial use: moderate to severe RA, mbr has had a trial and inadequate response or intolerance to ONE tumor necrosis antagonist agent. For PsA, mbr has had inadequate response to, or is intolerant of ONE conventional therapy [nonbiologic DMARDS] OR has a CI to nonbiologic DMARDS AND has had a trial and inadequate response or intolerance to ONE tumor necrosis factor (TNF) antagonist agent. For pediatric PsA, mbr has had a trial and inadequate response or intolerance to ONE tumor necrosis factor (TNF) agent. For Atopic Dermatitis, a non-corticosteroid systemic immunosuppressant (such as cyclosporine, azathioprine, or mycophenolate mofetil) has failed to achieve and maintain remission of low or mild disease activity state or are CI OR a Biologic therapy (such as dupilumab or tralokinumab) has failed to achieve and maintain remission of low or mild disease activity state or are contraindicated. For UC, mbr has had an inadequate response to, or is intolerant of ONE conventional therapy (such as 5- Aminosalicyclic acid products, systemic corticosteroids, or immunosuppressants [such as thiopurines]) OR has a CI to 5-ASA products or systemic corticosteroids or thiopurines AND individual has had a trial and inadequate response or intolerance to one tumor necrosis factor (TNF) antagonist agents. For CD, mbr has had an inadequate response to, or is intolerant of ONE conventional therapy (such as systemic corticosteroids or immunosuppressants [such as thiopurines or methotrexate]) OR has a CI to systemic corticosteroids or thiopurines or methotrexate AND has had a trial and inadequate response or intolerance to ONE tumor necrosis factor (TNF) antagonist agents. For AS, individual has had an inadequate response to, or is intolerant of ONE conventional therapy [such as NSAIDs or nonbiologic DMARDS (such as sulfasalazine)] OR has a CI to NSAIDs or sulfasalazine AND has had a trial and inadequate response or intolerance to ONE tumor necrosis factor (TNF) antagonist agents. For NR-axSpA, mbr has had an inadequate response to, or is intolerant of ONE conventional therapy [such as NSAIDs or</p>

PA Criteria	Criteria Details
	<p>nonbiologic DMARDs] (ACR 2019) OR has a CI to NSAIDs or nonbiologic DMARD. For PJIA, mbr has had an inadequate response to, or is intolerant of conventional therapy [nonbiologic DMARDS (such as methotrexate)] OR has a CI to MTX AND has had a trial and inadequate response or intolerance to ONE TNF antagonist agents. For Continuation requests, there is clinically significant improvement or stabilization in clinical signs and symptoms of disease and has been receiving and is maintained on a stable dose of Rinvoq.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Rozlytrek

---

## Products Affected

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG
- ROZLYTREK ORAL PACKET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For NSCLC, ROS1 mutation status. For solid tumor, NTRK gene fusion status.
<b>Age Restrictions</b>	For metastatic non-small cell lung cancer (NSCLC), 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual is using as monotherapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Rubraca

## Products Affected

- RUBRACA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Written or verbal attestation is provided for confirmation of mutations where applicable based on use/diagnosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For metastatic castration-resistant prostate cancer (mCRPC), with a deleterious BRCA mutation (germline and/or somatic), Individual had been treated with androgen-receptor directed therapy and a taxane-based chemotherapy AND is using a gonadotropin-releasing hormone (GnRH) analog (e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix)) concurrently or have had a bilateral orchiectomy and using as a single agent.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Rydapt

---

## Products Affected

- RYDAPT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has confirmed written or verbal attestation is provided for confirmation of mutations where applicable based on use/diagnosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Sabril

## Products Affected

- *vigabatrin oral packet*
  - *vigabatrin oral tablet*
  - VIGADRONE ORAL PACKET
  - VIGADRONE ORAL TABLET
- VIGPODER

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	For infantile spasm 1 month to 2yr old. For seizure 2 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 YEAR.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Scemblix

---

## Products Affected

- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For CML, Ph status, T315I status.
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Signifor IR

## Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of Cushings disease has been verified by, or in consultation with, a board-certified endocrinologist who has reviewed and verified the test results (including but not limited to: 24-hour urinary free cortisol (UFC) test, Dexamethasone suppression test (DST), Late-night salivary cortisol (LNSC) test) that are indicative of a positive test.
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Sirturo

---

## Products Affected

- SIRTURO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has a diagnosis of pulmonary multidrug-resistant tuberculosis (MDR-TB) or pulmonary extensively drug-resistant tuberculosis (XDR-TB) or pulmonary pre-extensively drug-resistant tuberculosis (pre-XDR-TB) AND the individual is using in combination with other anti-infectives (WHO 2019).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Skyrizi

## Products Affected

- SKYRIZI INTRAVENOUS MG/2.4ML
- SKYRIZI PEN
- SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE 180 MG/1.2ML, 360
- SKYRIZI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of chronic moderate to severe (that is, extensive or disabling) plaque psoriasis (Ps) with either of the following (AAD 2019): 1. Patient has greater than or equal to 3% body surface area (BSA) with plaque psoriasis OR 2. less than 3% BSA with plaque psoriasis involving sensitive areas or areas that significantly impact daily function (such as palms, soles of feet, head/neck, or genitalia).
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For initial use: dx of chronic plaque psoriasis (Ps), individual has had an inadequate response to, or is intolerant of phototherapy or any ONE systemic therapy (such as acitretin, cyclosporine, or methotrexate) OR has a contraindication to phototherapy, acitretin, cyclosporine, and methotrexate. For moderate to severe Crohns disease (CD) IV induction, Individual has had an inadequate response to, or is intolerant of ONE conventional therapy (such as systemic corticosteroids or immunosuppressants [such as thiopurines or methotrexate]) OR has a CI to systemic corticosteroids or thiopurines or methotrexate. For CD SQ maintenance therapy, individual has completed the intravenous induction doses with Skyrizi and will be using subcutaneous Skyrizi for maintenance therapy. For UC IV Induction, mbr has had an inadequate response to or is intolerant of conventional therapy (such as 5-Aminosalicylic acid products, systemic corticosteroids, or immunosuppressants [such as thiopurines]) OR has a CI to 5-ASA products or systemic corticosteroids or thiopurines. For UC SQ maintenance therapy, individual has completed the iv induction doses with Skyrizi and will be using sq Skyrizi for maintenance therapy. For Continuation use: there is improvement or stabilization in clinical signs and symptoms of disease AND has been receiving and is maintained on a stable dose of Skyrizi.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Solaraze

---

## Products Affected

- *diclofenac sodium external gel 3 %*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Dx of Actinic Keratosis
<b>Age Restrictions</b>	18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Somatuline Depot

## Products Affected

- *Ianreotide acetate*
- SOMATULINE DEPOT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of acromegaly has been verified by, or in consultation with, a board-certified endocrinologist who has reviewed and verified the test results (including but not limited to: Insulin-like Growth Factor 1 levels, Oral Glucose Tolerance Test with associated Growth Hormone (GH) levels) that are indicative of a positive test.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Somavert

## Products Affected

- SOMAVERT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Dx of acromegaly has been verified by, or in consultation with, a board-certified endocrinologist who has reviewed and verified the test results (including but not limited to: Insulin-like Growth Factor 1 levels, Oral Glucose Tolerance Test with associated Growth Hormone (GH) levels) that are indicative of a positive test AND member has had an inadequate response to surgery and/or radiation OR Surgery and/or radiation therapy are not an option.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Soriatane

## Products Affected

- *acitretin*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For severe psoriasis, if individual is a female of reproductive age, has met one of the following: (A) Individual is unresponsive to other therapies OR (B) has a clinical condition that contraindicates the use of other treatments.
<b>Age Restrictions</b>	For severe psoriasis, individual is greater than 18 years of age.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Spravato

---

## Products Affected

- SPRAVATO (56 MG DOSE)
- SPRAVATO (84 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Individual is 18 years of age or older.
Prescriber Restrictions	
Coverage Duration	Initial 3 months, continuation 1 year. MDD with acute suicidal ideation or behavior: 1 year

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For initial use, individual is using for the tx of depressive sx with major depressive disorder (MDD) with acute suicidal ideation or behavior AND has a dx of MDD without psychotic features according to DSM-5 (Fu 2020, Ionescu 2020) AND is judged to be at risk for suicide by a clinician based on consideration of suicidal behavior, expressed suicidal ideation or overall clinical assessment consistent with significant continuing risk of suicide AND will use Spravato as monotherapy OR in addition to antidepressant therapy. Individual has been diagnosed with moderate to severe major depressive disorder AND had an inadequate response to the maximum tolerated dose of two antidepressant therapies during the current major depressive episode (MDE) as defined by less than 50% reduction in symptom severity using a standard rating scale that reliably measures depressive symptoms AND will use Spravato in addition to antidepressant therapy. For continuation, individual has had at least a 50% reduction in symptoms of treatment resistant moderate to severe depression compared to baseline using a standard rating scale that reliably measures depressive symptoms AND will use Spravato as monotherapy OR in addition to antidepressant therapy.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Sprycel

## Products Affected

- *dasatinib*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	The member has one of the following mutations: T315I/A, F317L/V/I/C or V299L.
<b>Required Medical Information</b>	For CML/ALL, Philadelphia chromosome status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Stelara

---

## Products Affected

- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of moderate to severe plaque psoriasis with either of the following: Patient has greater than 3% of body surface area with plaque psoriasis OR Less than or equal to 3% of body surface area with plaque psoriasis involving sensitive areas or areas that would significantly impact daily function (such as palms, soles of feet, head/neck, or genitalia).
<b>Age Restrictions</b>	Individual is 18 years of age or older. For Plaque Psoriasis (Ps), Psoriatic Arthritis (PsA), age 6 and older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For initial use: chronic plaque psoriasis, individual has had an inadequate response to or is intolerant of phototherapy or any ONE systemic therapy (for example acitretin, methotrexate, cyclosporine) OR has a CI to phototherapy, acitretin, cyclosporine, and methotrexate. For psoriatic arthritis, individual has had an inadequate response to or is intolerant of ONE conventional therapy [nonbiologic DMARDS] OR has a CI to nonbiologic DMARDS. For Initial IV use in Crohns disease (CD), individual has had an inadequate response to or is intolerant of ONE conventional therapy (such systemic corticosteroids, or immunosuppressants [such as thiopurines or methotrexate]) OR has a CI to systemic corticosteroids or thiopurines or methotrexate. For initial SQ use in CD, mbr has completed IV induction dose with ustekinumab and will be using SQ ustekinumab for maintenance therapy. For Initial IV use in Ulcerative Colitis (UC), individual has had an inadequate response to or is intolerant of ONE conventional therapy (such as 5- Aminosalicyclic acid products, systemic corticosteroids, or immunosuppressants [such as thiopurines]) OR has a CI to 5-ASA products or systemic corticosteroids or thiopurines. For Initial SQ use in UC, mbr has completed the IV induction dose with ustekinumab and will be using SQ ustekinumab for maintenance therapy. For Continuation use, mbr has been receiving and is maintained on a stable dose of Ustekinumab and there is confirmation (written or verbal) of clinically significant improvement or stabilization in clinical signs and symptoms of disease.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Stivarga

---

## Products Affected

- STIVARGA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Written or verbal attestation is provided for confirmation of mutations or disease progression where applicable based on use/diagnosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For gastrointestinal stromal tumors (GIST), individual has had progression after monotherapy with imatinib and sunitinib
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Stromectol

---

## Products Affected

- *ivermectin oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	For the treatment or prophylaxis of COVID-19.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Sutent

---

## Products Affected

- *sunitinib malate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# Synagis

## Products Affected

- SYNAGIS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Individual is using when the following are met: A) Maximum of Five (5) doses of palivizumab for infants during the first RSV season within the first year of life: Born before 29 weeks, 0 days gestation (up to and including 28 weeks, 6 days) and younger than 12 months of age at the start of the RSV season OR Chronic lung disease (CLD) of prematurity defined as birth at less than 32 weeks, 0 days gestation and a requirement for greater than 21% oxygen for at least 28 days after birth OR Hemodynamically significant congenital heart disease (CHD) (including infants with acyanotic heart disease who are receiving medication to control congestive heart failure and will require cardiac surgical procedures and infants with moderate to severe pulmonary hypertension OR infants with anatomic pulmonary abnormalities (i.e., tracheal ring) or a neuromuscular condition that impairs the ability to clear secretions from the upper airway because of ineffective cough OR Cystic fibrosis with clinical evidence of chronic lung disease or nutritional compromise (weight for length less than tenth percentile). B) Maximum of five (5) doses of palivizumab for children younger than 24 months of age with any of the following: Profoundly immunocompromised, including severe combined immunodeficiency, advanced acquired immunodeficiency syndrome, undergoing organ or hematopoietic stem cell transplant, or an absolute lymphocyte count of less than 100 cell/mm<sup>3</sup> OR undergoing cardiac transplantation.</p>
<b>Age Restrictions</b>	

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	5 Months.
<b>Other Criteria</b>	C) An additional dose of palivizumab may be allowed for children younger than 24 months of age who have approval for a course of treatment and who undergo cardiopulmonary bypass for a surgical procedure. D) A maximum of 5 doses of palivizumab prophylaxis may be approved for children during their second RSV season (the second RSV season may fall in the first or second year of life) with any of the following: (i) for preterm infant born at less than 32 weeks, 0 days gestation who required at least 28 days of oxygen after birth and continues to require medical intervention within 6 months of the start of the second RSV season (including supplemental oxygen, chronic corticosteroid therapy, or diuretics) or (ii) Cystic fibrosis with severe lung disease (history of hospitalization, abnormal chest x-ray or CT scan) or weight for length less than tenth percentile.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Syprine

## Products Affected

- *trientine hcl*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has a diagnosis of Wilsons Disease as confirmed by two of the following (AASLD 2022): (A) Serum ceruloplasmin less than 20 mg/DI (B) Presence of Kayser-Fleischer rings (C) 24-hour urinary copper is greater than 40 mcg/day (D) Liver biopsy findings consistent with Wilsons Disease (E) Genetic testing findings consistent with Wilsons Disease.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Tabrecta

## Products Affected

- TABRECTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For recurrent, advanced or metastatic non-small cell lung cancer (NSCLC), Individual has mesenchymal-epithelial transition (MET) exon 14 skipping positive tumors AND individual has not received treatment with another MET exon 14 skipping-targeted agent, such as crizotinib. For metastatic NSCLC, individual has MET exon 14 skipping positive tumors. For advanced or metastatic NSCLC, individual has high level MET amplification (greater than or equal to 10 gene copies) (Wolf 2020).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual is using Tabrecta (capmatinib) as monotherapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Tafinlar

---

## Products Affected

- TAFINLAR ORAL CAPSULE
- TAFINLAR ORAL TABLET SOLUBLE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Melanoma, NSCLC, ATC, Solid Tumors, LGG, BRAF V600 mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Tagrisso

---

## Products Affected

- TAGRISSO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For NSCLC, written or verbal attestation is provided to confirm EGFR mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Talzenna

---

## Products Affected

- TALZENNA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Breast cancer BRCA mutation status. For mCRPC, HRR mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year.
<b>Other Criteria</b>	For mCRPC, individual is concomitantly receiving a gonadotropin-releasing hormone (GnRH) analog or has had a bilateral orchiectomy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Tarceva

---

## Products Affected

- *erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For NSCLC, EGFR-sensitizing mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 YEAR.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Targretin

---

## Products Affected

- *bexarotene external*
- *bexarotene oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# Tasigna

---

## Products Affected

- TASIGNA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Tazorac

## Products Affected

- *tazarotene external cream 0.1 %*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	May not be approved for cosmetic purposes such as, but not limited to the following: Cosmetic purposes, Photoaging, Wrinkles, Hyperpigmentation, Sun damage, or Melasma.
<b>Required Medical Information</b>	For psoriasis, individual has up to 20% of body surface area involvement.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For psoriasis, individual has had a prior trial and inadequate response to either of the following (AAD 2009): Any two (2) topical corticosteroids or any one (1) topical corticosteroids plus calcipotriene. For psoriasis use greater than 1 year, efficacy must be documented for continued use. Documentation may include chart notes, consultation notes.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Tazverik

---

## Products Affected

- TAZVERIK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ECOG performance status of 0-2. Written or verbal attestation is provided for confirmation of mutations where applicable based on use/diagnosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Tecvayli

---

## Products Affected

- TECVAYLI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For MM, current Eastern Cooperative Group (ECOG) performance status of 0-1 AND No prior treatment with any B cell maturation antigen (BCMA) targeted therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Tepmetko

---

## Products Affected

- TEPMETKO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For NSCLC, mesenchymal-epithelial transition (MET) exon 14 skipping alterations status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For recurrent, advanced, or metastatic Non-Small Cell Lung Cancer (NSCLC), individual is using as monotherapy AND has not received treatment with another MET exon 14 skipping-targeted agent.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Teriflunomide Agents

---

## Products Affected

- *teriflunomide*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Testosterone Inj

## Products Affected

- DEPO-TESTOSTERONE INTRAMUSCULAR SOLUTION 100 MG/ML
- *testosterone cypionate intramuscular solution 100 mg/ml*
- *testosterone enanthate intramuscular solution*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Prior to starting testosterone therapy, an initial and a repeat (at least 24 hours apart) morning total testosterone level is provided to confirm a low testosterone serum level indicating one of the following: (1) Individual is 70 years of age or younger with a serum testosterone level of less than 300 ng/dL OR (2) Individual is over 70 years of age with a serum testosterone level of less than 200 ng/dL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For initial use of replacement therapy, Individual has a dx of (1) primary hypogonadism (congenital or acquired) such as but not limited to: Cryptorchidism OR Bilateral torsion OR Vanishing testis syndrome OR orchitis OR Orchiectomy OR Klinefelter Syndrome OR Chemotherapy OR Toxic damage from alcohol or heavy metals OR idiopathic primary hypogonadism. Or (2) Hypogonadotropic hypogonadism (congenital or acquired), such as but not limited to: Idiopathic luteinizing hormone-releasing hormone (LHRH deficiency) OR Pituitary-hypothalamic injury AND Individual presents with symptoms associated with hypogonadism, such as but not limited to, at least one of the following: (a) Reduced sexual desire (libido) and activity or (b) Decreased spontaneous erections or (c) Breast discomfort/gynecomastia or (d) Loss of body (axillary and pubic) hair, reduced need for shaving or (e) Very small (especially less than 5 mL) or shrinking testes or (f) Inability to father children or low/zero sperm count or (g) Height loss, low trauma fracture, low bone mineral density or (h) Hot flushes, sweats or (i) Other less specific signs and symptoms including decreased energy, depressed mood/dysthymia, irritability, sleep disturbance, poor concentration/memory, diminished physical or work performance. For Continuation of Testosterone Inj agents for replacement therapy, (a) Individual met all diagnostic criteria for initial therapy and (b) Individual has had serum testosterone level measured in the previous 180 days and (c) Individual has obtained clinical benefits as noted by symptom improvement. For treatment of delayed puberty when ALL the criteria below are met: Individual is using to stimulate puberty and has documented (verbal or written) few to no signs of puberty. For tx of breast cancer when the following are met: Female 1-5 years post-menopause and Individual is using secondarily for advanced inoperable metastatic (skeletal) breast cancer OR Premenopausal female who has benefited from oophorectomy and is considered to have a hormone responsive tumor. For tx of individual with low testosterone and HIV-associated weight loss and wasting. For gender</p>
	<p>dysphoria/incongruence individuals who meet ALL the following criteria: Individual has experienced puberty to at least Tanner Stage 2 AND has a diagnosis of gender dysphoria/incongruence.</p>
<b>Indications</b>	All Medically-accepted Indications.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Thalomid

---

## Products Affected

- THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Tibsovo

---

## Products Affected

- TIBSOVO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For AML, Cholangiocarcinoma, and MDS, IDH1 mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Topical Androgens

## Products Affected

- *testosterone transdermal gel 12.5 mg/act (1%), 25 mg/2.5gm (1%), 50 mg/5gm (1%)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	For primary or hypogonadotropic hypogonadism, individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For Initial use: Individual has a dx of (1) primary hypogonadism (congenital or acquired) [for example, Cryptorchidism OR Bilateral torsion OR orchitis OR Vanishing testis syndrome OR Orchiectomy OR Klinefelter Syndrome OR Chemotherapy OR Toxic damage from alcohol or heavy metals OR idiopathic primary hypogonadism]. Or (2) Hypogonadotropic hypogonadism (congenital or acquired) [for example, Idiopathic luteinizing hormone-releasing hormone (LHRH deficiency), OR Pituitary-hypothalamic injury.] Individual is using for a diagnosis of gender Dysphoria/incongruence (Coleman 2022) AND has experienced puberty to at least Tanner Stage 2. For continuation use for primary or hypogonadotropic hypogonadism, Individual meets all criteria for initial therapy AND has had serum testosterone level measured in the previous 180 days AND Individual has obtained clinical benefits as noted by symptom improvement.
<b>Indications</b>	All Medically-accepted Indications.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Topical Tretinoin Agents

---

## Products Affected

- *tretinoin external cream 0.05 %, 0.1 %*
- *tretinoin external gel 0.01 %, 0.025 %*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Topical tretinoin agents may not be approved for cosmetic purposes such as, but not limited to the following: Photoaging, Wrinkles, Hyperpigmentation, Sun damage, Melasma.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Transmucosal Fentanyl Citrate

## Products Affected

- *fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individual is 16 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Individual has a diagnosis of active cancer with breakthrough cancer (including but not limited to metastatic or locally invasive cancer for which the individual is currently seeking treatment) with breakthrough cancer pain AND Individual is already receiving opioid therapy and is TOLERANT to opioid therapy as defined as receiving around the clock medicine consisting of one of the following: At least 60mg morphine per day, OR At least 25mcg/hr transdermal fentanyl/hour, OR At least 30mg of oxycodone daily, OR At least 8mg of oral hydromorphone daily, OR At least 25mg of oral oxymorphone daily, OR At least 60mg of oral hydrocodone daily, OR An equianalgesic dose of another opioid for a week or longer. Individual will also continue around the clock opioids when taking transmucosal fentanyl Citrate for cancer related breakthrough pain.
<b>Indications</b>	All Medically-accepted Indications.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Truqap

---

## Products Affected

- TRUQAP

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has the applicable mutations based on use/diagnosis. Individual is HR positive, HER2 negative breast cancer (defined as IHC 0 or 1 plus or IHC 2 plus/ISH negative).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Tukysa

---

## Products Affected

- TUKYSA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has the applicable mutations based on use/diagnosis. HER2-positive (HER2+) breast cancer is confirmed by one of the following: (a) Immunohistochemistry (IHC) is 3 + or (b) In situ hybridization (ISH) positive.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Turalio

---

## Products Affected

- TURALIO ORAL CAPSULE 125 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Tykerb

---

## Products Affected

- *lapatinib ditosylate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cancer has been confirmed HER2 positive. HER 2 overexpression confirmed (written or verbal) by one of the following: (a) Immunohistochemistry (IHC) 3+ or (b) In situ hybridization (ISH) positive.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Uceris

---

## Products Affected

- *budesonide er oral tablet extended release 24 hour*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 years of age or older.
Prescriber Restrictions	
Coverage Duration	1 year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Valchlor

---

## Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Vancocin

---

## Products Affected

- *vancomycin hcl oral capsule*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual is being treated for enterocolitis caused by Staphylococcal aureus including methicillin-resistant strains. Individual is being treated for clostridium Clostridiodes difficile-associated.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Vanflyta

---

## Products Affected

- VANFLYTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For AML, FLT3 internal tandem duplication (ITD)-positive mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Venclexta

---

## Products Affected

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Verquvo

## Products Affected

- VERQUVO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For initial use, individual has experienced one of the following: (A) Heart failure hospitalization within 6 months OR (B) Use of intravenous outpatient diuretics within 3 months AND Individual will be taking Verquvo (vericiguat) in combination with the following (Armstrong 2020): (A) Entresto (sacubitril/valsartan), angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) unless contraindicated or not tolerated AND (B) Beta-blocker (bisoprolol, carvedilol, metoprolol succinate) unless contraindicated or not tolerated.
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For Continuation, there is clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to improvement in heart failure symptoms, reduction in heart failure related physical limitations, reduction in hospitalizations) AND continues to use Verquvo (vericiguat) in combination with Entresto (sacubitril/valsartan), angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) unless contraindicated or not tolerated AND continues to use Verquvo (vericiguat) in combination with beta-blocker (bisoprolol, carvedilol, metoprolol succinate) therapy unless contraindicated or not tolerated.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Verzenio

---

## Products Affected

- VERZENIO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For Breast cancer, HR status and HER2 status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For early Breast Cancer, individual is only using Verzenio in this combination for a total of 24 months (2 years)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Vfend

## Products Affected

- *voriconazole intravenous*
- *voriconazole oral suspension reconstituted*
- *voriconazole oral tablet 200 mg, 50 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual is currently transitioning from inpatient treatment (hospital/medical facility) to an outpatient (home) setting and requires continued therapy for an organism susceptible to Vfend (voriconazole). Or mbr is using for a FDA approved use or supported by CMS approved compendia.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Vidaza

---

## Products Affected

- *azacitidine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Vittrakvi

## Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Written or verbal attestation to confirm genetic test results show the tumor has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For Vittrakvi (larotrectinib) oral solution requests, individual is unable to swallow the oral capsule dose form due to a clinical condition, but not limited to the following: (a) Dysphagia OR (b) individual?s age.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Vizimpro

---

## Products Affected

- VIZIMPRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For NSCLC, EGFR mutation status.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Vonjo

---

## Products Affected

- VONJO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Individual is 18 years of age or older
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Voranigo

---

## Products Affected

- VORANIGO ORAL TABLET 10 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For Astrocytoma, Oligodendroglioma, IDH1/IDH2 mutation status.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	Individual is using Voranigo (vorasidenib) as a single agent.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Vosevi

## Products Affected

- VOSEVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation is provided for a diagnosis of chronic hepatitis C (CHC) infection, which includes a genotype and positive HCV RNA result (AASLD/IDSA 2017, CDC 2013) AND Individual has received baseline evaluation for liver fibrosis to guide appropriate therapy AND Individual does not have a short life expectancy (less than 12 months owing to non-liver related comorbid conditions) that cannot be remediated by treating HCV, by transplantation or other directed therapy (AASLD/IDSA 2017).
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Criteria will be applied consistent with current AASLD/IDSA guidance.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>Criteria will be applied consistent with current AASLD/IDSA guidance. For Genotype 1, 1a, Individual has had a trial of and inadequate response to Harvoni (sofosbuvir/ledipasvir) OR Individual is currently on and completing a course of therapy with Vosevi OR has one of the following: (1) Documented hypersensitivity, as manifested by a severe allergic reaction to any ingredient in Harvoni(sofosbuvir/ledipasvir) which is not also in Vosevi OR (2) concurrently using an agent that cannot be substituted with another agent or temporarily discontinued and is contraindicated or not recommended for concomitant use with the preferred regimen or regimens OR (3) Individual failed to achieve a sustained viral response (SVR) or relapsed after achieving a SVR during a prior successfully completed Hepatitis C regimen containing an NS5A inhibitor OR (4) Individual has unique disease characteristic to which the preferred regimen(s) is not recommended (examples include specific genotype subtype, resistance-associated substitution (RAS) or polymorphism) . For Genotype 4, Individual has had a trial of and inadequate response to Harvoni(sofosbuvir/ledipasvir) or Epclusa(sofosbuvir/velpatasvir) OR Individual is currently on and completing a course of therapy with Vosevi OR has one of the following: (1) Documented hypersensitivity, as manifested by a severe allergic reaction to any ingredient in Harvoni(sofosbuvir/ledipasvir) or Epclusa(sofosbuvir/velpatasvir) which is not also in Vosevi OR (2) concurrently using an agent that cannot be substituted with another agent or temporarily discontinued and is contraindicated or not recommended for concomitant use with the preferred regimen or regimens OR (3) Individual failed to achieve a sustained viral response (SVR) or relapsed after achieving a SVR during a prior successfully completed Hepatitis C regimen containing an NS5A inhibitor OR (4) Individual has a unique disease characteristic to which the preferred regimen(s) is not recommended (examples include specific genotype subtype, resistance-associated substitution (RAS) or polymorphism).</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# VOTRIENT

---

## Products Affected

- *pazopanib hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Vowst

## Products Affected

- VOWST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has had at least three episodes of Clostridiodes difficile infection (initial episode and two recurrences) treated with antibiotic therapy (including Difucid, metronidazole or oral vancomycin) (IDSA/SHEA 2021) AND Current episode of Clostridiodes difficile infection has been verified (written or verbal) with a positive stool test for Clostridiodes difficile toxin AND treatment will be initiated within 2 to 4 days of completing antibiotic treatment for the current Clostridiodes difficile infection episode.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Month.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Welireg

---

## Products Affected

- WELIREG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of VHL is confirmed (written or verbal) by genetic testing demonstrating germline VHL alteration (NCT03401788).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	Using Welireg (belzutifan) as monotherapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Xalkori

---

## Products Affected

- XALKORI ORAL CAPSULE
- XALKORI ORAL CAPSULE SPRINKLE  
150 MG, 20 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For NSCLC, ALK or ROS1 mutation status. For ALCL and IMT, ALK mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# XENAZINE

---

## Products Affected

- *tetrabenazine oral tablet 12.5 mg, 25 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial: 3 months. Continuation: 1 year
<b>Other Criteria</b>	For continuation requests, individual has experienced an improvement in symptoms deemed to be clinically significant by the provider, and if using for Huntingtons disease, there is stabilization or improvement in total maximal chorea score.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Xermelo

## Products Affected

- XERMELO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial: 3 months. Continuation: 1 year
<b>Other Criteria</b>	For initial therapy: Individual is using in combination with somatostatin analog (SSA) therapy (such as but not limited to, lanreotide (Somatuline Depot), octreotide (Sandostatin)) AND individual has had an inadequate response on a stable dose of SSA monotherapy for at least 3 months. For continuation therapy requests: Individual has previously met the initiation criteria AND if improvements are confirmed after 12 weeks of treatment with Xermelo (telotristat ethyl) when added to SSA therapy AND Individual does not report severe constipation or severe persistent or worsening abdominal pain.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Xgeva

## Products Affected

- XGEVA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Skeletally mature adolescent is defined by at least one mature long bone [for example, closed epiphyseal growth plate of the humerus]. Hypercalcemia of malignancy is defined as an albumin corrected serum calcium level greater than 12.5 mg/dL (3.1 mmol/L).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For Hypercalcemia of malignancy, Refractory to recent (within the last 30 days) treatment with intravenous bisphosphonate therapy (for example, pamidronate, zoledronic acid).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Xifaxan - HE

---

## Products Affected

- XIFAXAN ORAL TABLET 550 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For the treatment of small intestinal bacterial overgrowth (ACG 2020).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Xolair

## Products Affected

- XOLAIR SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML, 300 MG/2ML, 75 MG/0.5ML
- XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML, 300 MG/2ML, 75 MG/0.5ML
- XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has Moderate to Severe Persistent Asthma AND has a positive skin test or in vitro reactivity to a perennial aeroallergen, AND individual has a pretreatment FEV1 less than 80% predicted AND IgE level is equal to or greater than 30 IU/ml. For nasal polyps, individual had an inadequate response to nasal corticosteroids as add-on maintenance treatment AND individual has a serum IgE level greater than or equal to 30 IU/mL. For IgE mediated food allergy, diagnosis is confirmed via clinical hx of IgE mediated food allergy demonstrated by moderate to severe symptoms (including but not limited to throat tightness, dyspnea/wheezing, clinically significant hypotension, generalized urticaria) or requiring administration of epinephrine or emergency medical care AND positive skin prick test or positive serum IgE test or positive food challenge AND has a serum Immunoglobulin E (IgE) level equal to or greater than 30 IU/mL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial: 6 months. Continuation: 1 Year.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>Initial Treatment: For moderate to severe persistent asthma, individual has had a minimum of 3 month trial and inadequate response or intolerance to ONE combination controller therapy (high dose of inhaled corticosteroids plus long-acting beta-2 agonists, Leukotriene modifiers, theophylline or oral corticosteroids)(GINA 2023). Continued treatment beyond 12 months is allowed when treatment has resulted in clinical improvement by one or more of the following: Decreased utilization of reliever medications OR Decreased frequency of exacerbations (defined as worsening of asthma that requires increase in inhaled corticosteroid dose or treatment with systemic corticosteroids) OR Increase in percent predicted FEV1 from pretreatment baseline OR Reduction in reported asthma- related symptoms, such as, but not limited to, wheezing, shortness of breath, coughing, fatigue, sleep disturbance, or asthmatic symptoms upon awakening. AND continues to use omalizumab in combination with inhaled corticosteroid-based controller therapy For chronic spontaneous urticaria, individual has had trial and inadequate response or intolerance to ONE potent antihistamine (AAAAI/ACAAI 2014). For continued use for CSU, treatment has resulted in clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to itch severity and hive count). For initial request for CRSwNP, the presence of nasal polyps have been demonstrated on one of the following (AAO-HNS2015): a) anterior rhinoscopy b) nasal endoscopy OR c) computed tomography AND individual has had trial and inadequate response to maintenance intranasal corticosteroids AND individual is refractory to or is ineligible or intolerant to the following (AAAAI/ACAAI 2014): a) systemic corticosteroids OR b) sinonasal surgery. For CRSwNP continuation requests, tx with Xolair has resulted clinically significant improvement in clinical signs and symptoms of disease (including but not limited to improvement in nasal congestion or reduced polyp size) AND continues to use Xolair in combo with maintenance intranasal corticosteroids. For</p>
	<p>initial and continued use for IgE mediated food allergy, individual will use omalizumab in combination with food allergen avoidance AND has a prescription for an auto-injectable epinephrine agent.</p>
<b>Indications</b>	All Medically-accepted Indications.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Xospata

---

## Products Affected

- XOSPATA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For AML, FLT3 mutation status.
<b>Age Restrictions</b>	Individual is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Xpovio

## Products Affected

- XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG
- XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (80 MG TWICE WEEKLY)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For (DLBCL), Individual must not have DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma, composite lymphoma (Hodgkins and non-Hodgkins lymphoma), primary mediastinal (thymic) large B-cell lymphoma (PMBL), or known central nervous system (CNS) lymphoma (NCT02227251).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Xtandi

---

## Products Affected

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	Individual is concomitantly receiving a gonadotropin-releasing hormone (GnRH) analog or has had a bilateral orchiectomy.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Xyrem

## Products Affected

- *sodium oxybate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For initial tx of Narcolepsy type 1 (narcolepsy with cataplexy) defined by the presence of daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months and at least one of the following (ICSD-3): (1) Clear cataplexy (defined as more than one episode of generally brief [less than 2 min]) usually bilaterally symmetrical, sudden loss of muscle tone with retained consciousness) AND (2) Multiple Sleep Latency Test (MSLT) showing one of the following: (a) MSLT of less than 8 minutes with evidence of two sleep-onset rapid eye movement periods (SOREMPs) or (b) At least one SOREMP on MSLT and a SOREMP (less than 15 minutes) on the preceding overnight polysomnography (PSG) OR (3) Cerebrospinal fluid hypocretin-1 deficiency (less than 100 pg/mL or less than one-third of the normative values with the same standardized assay).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial: 3 months. Continuation: 6 months

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>For initial tx, of Narcolepsy type 2 (narcolepsy without cataplexy) defined by the following: (1) Daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months AND (2) MSLT with one of the following: (a) MSLT of less than 8 minutes and evidence of two SOREMPs (ICSD-3, 2014) or (b) At least one SOREMP on MSLT and a SOREMP (less than 15 minutes) on the preceding overnight PSG AND (3) absence of cataplexy AND (4) Exclusion of alternative causes of excessive daytime sleepiness by history, physical exam and PSG. AND (5) Mbr has had a previous trial of and inadequate response or intolerance to TWO of the following medications: (A) One of the following wakefulness promoting medications: (i) Modafinil or (ii) Nuvigil (armodafinil) AND (B) One of the following stimulants: (i) Methylphenidate (ii) Dextroamphetamine or (iii) Amphetamine/dextroamphetamine salt immediate-release OR (6) Trials of wakefulness promoting agents and stimulant agents are not acceptable due to concomitant clinical situations including but not limited to the following: (1) Cardiovascular disease or (2) Drug interactions. Mbr has idiopathic hypersomnia defined by (1) daily periods of strong need to sleep or daytime lapses into sleep for more than 3 mon. (2) absence of cataplexy (3) Insuff sleep syndrome ruled out (if nec, by lack of improvement of sleepiness after adequate trial of increased nocturnal time in bed, preferably verified by at least 1 wk. of wrist actigraphy) (4) MSLT shows fewer than 2 SOREMPs OR No SOREMPs if the REM sleep latency period on the preceding overnights polysomnogram is 15min or less (5) The presence of at least one: MSLT shows mean sleep latency of 8 min or less OR total 24hr sleep time of 660 min or longer (typically 12-14 hrs) on 24-hr polysomnography monitoring (performed after the correction of chronic sleep deprivation) or by wrist actigraphy in assoc with a sleep log (avg over at least 7 days with unrestricted sleep) AND (6) hypersomolence or MSLT findings are not better explained by another sleep disorder, medical or neurologic disorder, mental disorder, med use or substance abuse.</p>
	<p>For continuation, use has resulted in a reduction in frequency of cataplexy attacks compared to baseline OR use has resulted in a reduction in excessive daytime sleepiness (EDS) as measured by improvement in Epworth Sleepiness Scale (ESS) measurements or Maintenance of Wakefulness Test (MWT) compared to baseline.</p>

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Zarxio

## Products Affected

- ZARXIO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Febrile neutropenic Individuals who are at high risk for infection-associated complications by any of the following: Expected prolonged (greater than 10 day) and profound (less than <math>0.1 \times 10</math> to the power of <math>9/L</math>) neutropenia, Age greater than 65 years, Pneumonia or other clinically documented infections, Hypotension and multi organ dysfunction (sepsis syndrome), Invasive fungal infection, Prior episode of febrile neutropenia, Hospitalized at the time of the development of fever. Primary prophylaxis of FN in patients who have a risk of FN of 20% or greater based on chemotherapy regimens. OR when the risk of developing FN is greater than or equal to 10% and less than 20% based on chemotherapy in patients who have risk factors for FN including any of the following: age greater than 65 years, Poor performance status (ECOG status 3-4) or HIV infection (in particular, those with low CD4 counts (less than or eq <math>450/?L</math>) but chemotherapy still indicated (Lyman 2014), Prior radiation therapy (within previous 1 year) (Terbuch 2018) (Fujiwara 2017) (Shigeta 2015), Bone marrow involvement by tumor producing cytopenias, persistent neutropenia (ANC less than <math>1500mm^3</math>), poor renal function (GFR less than <math>60mL/min</math>) , liver dysfunction (liver function tests at least 2x upper limit of normal or bilirubin gr than <math>2.0 mg/dL</math>) (Lyman 2014) (Aagaard 2018), recent surgery performed as part of cancer management within previous 30 days (not to include a procedure such as port placement, drain placement, IVC filter, etc) (Lyman 2014, Aagaard 2018). History of active infection within previous 60 days(Lyman 2014, Aagaard 2018). Current open wound and chemotherapy cannot be delayed (Lyman 2014, Aagaard 2018).</p>

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>Secondary Prophylaxis for patients who experienced a neutropenic complication from a prior cycle of chemotherapy (for which primary prophylaxis was not received), in which a reduced dose may compromise disease-free or overall survival or treatment outcome. Using for adjunctive tx for FN and has been prophylactic therapy with GCSF or has not received prophylactic therapy with a GCSF and who are at high risk for infection-associated complications. Use in individuals with acute myeloid leukemia (AML) shortly after the completion of induction or repeat induction chemotherapy, or after the completion of consolidation chemotherapy for AML. For tx of moderate to severe aplastic anemia. Tx of severe neutropenia in individuals with hairy cell leukemia. For myelodysplastic syndromes (MDS) with severe neutropenia (absolute neutrophil count (ANC) less than or equal to 500 mm<sup>3</sup> or experiencing recurrent infection. For myelodysplastic syndrome with ring sideroblasts (MDS-RS) or MDS/MPN-RS-T and using in combination with luspatercept-aamt. For dose dense therapy (treatment given more frequently, such as every two weeks instead of every three weeks) for adjuvant treatment of breast cancer. For chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g., fever, infections, oropharyngeal ulcers) in symptomatic individuals with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia. For tx of (non-chemotherapy) drug-induced neutropenia. For tx of low neutrophil counts in individuals with glycogen storage disease type 1b. For tx of neutropenia associated with human immunodeficiency virus (HIV) infection and antiretroviral therapy. In individuals receiving radiation therapy in the absence of chemotherapy if prolonged delays secondary to neutropenia are expected. After accidental or intentional total body radiation of myelosuppressive doses (greater than 2 Grays [Gy] (such as Hematopoietic Syndrome of Acute Radiation Syndrome). After hematopoietic progenitor stem cell transplant (HPCT/HSCT) to promote myeloid reconstitution or when engraftment is delayed or has failed. To mobilize progenitor cells into peripheral blood for</p>

PA Criteria	Criteria Details
	<p>collection by leukapheresis, as an adjunct to peripheral blood/hematopoietic stem cell transplantation (PBSCT/PHSCT). Use as an alternate or adjunct to donor leukocyte infusions (DLI) in individuals with leukemic relapse after an allogeneic hematopoietic stem cell transplant. For tx for hematopoietic cell mobilization in combination with plerixafor. For Wilms Tumor (Nephroblastoma) and using with Regimen M and Regimen I for one of the following courses: Cyclophosphamide and etoposide OR Cyclophosphamide, doxorubicin, and vincristine. For autologous hematopoietic stem cell (HSC) mobilization as part of the development of an FDA-approved ex vivo gene therapy (e.g. Zynteglo (betibeglogene autotemcel)). For hematopoietic cell mobilization for autologous donors in combination with motixafortide.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Zejula

---

## Products Affected

- ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For ovarian cancer, BRCA mutation status.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Zelboraf

---

## Products Affected

- ZELBORAF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For Melanoma, and ECD, BRAF V600 mutation status.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Zolinza

---

## Products Affected

- ZOLINZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Zometa

---

## Products Affected

- *zoledronic acid intravenous concentrate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Individual has bone metastases documented on imaging or bone pain associated with imaging-documented metastases from breast, prostate, lung, kidney, thyroid, or other solid tumors.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	For Breast cancer, prevention of bone loss secondary to adjuvant hormone therapy OR Hypercalcemia of malignancy OR treatment of Multiple myeloma OR Prevention of osteoporosis during androgen deprivation therapy in prostate cancer OR Bone disease associated with Langerhans Cell Histiocytosis.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025



# Zydelig

---

## Products Affected

- ZYDELIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 Year.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Zykadia

---

## Products Affected

- ZYKADIA ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For NSCLC, ALK mutation status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 Year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Zytiga

---

## Products Affected

- *abiraterone acetate oral tablet 250 mg, 500 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Individual is concomitantly receiving a gonadotropin-releasing hormone (GnRH) analog or has had a bilateral orchiectomy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025

# Zyvox

## Products Affected

- *linezolid oral suspension reconstituted*
- *linezolid oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	vancomycin-resistant enterococcus faecium (VRE) infection OR methicillin-resistant S. aureus (MRSA) infection. Or Infection that is caused by other susceptible gram-positive organisms.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	30 days. 1 year for MDR-TB, XDR-TB, non-tuberculous mycobacterial infection.
<b>Other Criteria</b>	If individual started treatment with Linezolid in the hospital and requires continued outpatient therapy for an organism susceptible to linezolid. For diagnosis of pulmonary multidrug-resistant tuberculosis (MDR-TB) or pulmonary extensively drug-resistant tuberculosis (XDR-TB) (WHO 2019), linezolid will be used in combination with other anti-infectives (WHO 2019). For non-tuberculous mycobacterial infection (including but not limited to M. fortuitum) (ATS/ERS/ESCMID/IDSA 2020) AND will be used in combination with other anti-infectives (ATS/ERS/ESCMID/IDSA 2020).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0114\_25\_3012943\_0000\_I\_C  
1074448MUMENMUB

EFFECTIVE DATE 04/01/2025